<abstracts-retrieval-response xmlns="http://www.elsevier.com/xml/svapi/abstract/dtd" xmlns:dn="http://www.elsevier.com/xml/svapi/abstract/dtd" xmlns:ait="http://www.elsevier.com/xml/ani/ait" xmlns:ce="http://www.elsevier.com/xml/ani/common" xmlns:cto="http://www.elsevier.com/xml/cto/dtd" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:xocs="http://www.elsevier.com/xml/xocs/dtd" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><coredata><prism:url>https://api.elsevier.com/content/abstract/scopus_id/85062329074</prism:url><dc:identifier>SCOPUS_ID:85062329074</dc:identifier><eid>2-s2.0-85062329074</eid><pubmed-id>30813952</pubmed-id><prism:doi>10.1186/s12974-019-1439-y</prism:doi><article-number>50</article-number><dc:title>Genetic variability of inflammation and oxidative stress genes does not play a major role in the occurrence of adverse events of dopaminergic treatment in Parkinson's disease</dc:title><prism:aggregationType>Journal</prism:aggregationType><srctype>j</srctype><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><citedby-count>0</citedby-count><prism:publicationName>Journal of Neuroinflammation</prism:publicationName><dc:publisher>BioMed Central Ltd.info@biomedcentral.com</dc:publisher><source-id>50032</source-id><prism:issn>17422094</prism:issn><prism:volume>16</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:coverDate>2019-02-27</prism:coverDate><openaccess>1</openaccess><openaccessFlag>true</openaccessFlag><dc:creator><author seq="1" auid="57193522851"><ce:initials>S.</ce:initials><ce:indexed-name>Redensek S.</ce:indexed-name><ce:surname>Redenšek</ce:surname><ce:given-name>Sara</ce:given-name><preferred-name><ce:initials>S.</ce:initials><ce:indexed-name>Redenšek S.</ce:indexed-name><ce:surname>Redenšek</ce:surname><ce:given-name>Sara</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/57193522851</author-url><affiliation id="60021802" href="https://api.elsevier.com/content/affiliation/affiliation_id/60021802"/></author></dc:creator><dc:description><abstract xmlns="" original="y" xml:lang="eng"><publishercopyright>© 2019 The Author(s).</publishercopyright><ce:para>Background: Inflammation and oxidative stress are recognized as important contributors to Parkinson's disease pathogenesis. As such, genetic variability in these pathways could have a role in susceptibility for the disease as well as in the treatment outcome. Dopaminergic treatment is effective in management of motor symptoms, but poses a risk for motor and non-motor adverse events. Our aim was to evaluate the impact of selected single-nucleotide polymorphisms in genes involved in inflammation and oxidative stress on Parkinson's disease susceptibility and the occurrence of adverse events of dopaminergic treatment. Methods: In total, 224 patients were enrolled, and their demographic and clinical data on the disease course were collected. Furthermore, a control group of 146 healthy Slovenian blood donors were included for Parkinson's disease' risk evaluation. Peripheral blood was obtained for DNA isolation. Genotyping was performed for NLRP3 rs35829419, CARD8 rs2043211, IL1β rs16944, IL1β rs1143623, IL6 rs1800795, CAT rs1001179, CAT rs10836235, SOD2 rs4880, NOS1 rs2293054, NOS1 rs2682826, TNF-α rs1800629, and GPX1 rs1050450. Logistic regression was used for analysis of possible associations. Results: We observed a nominally significant association of the IL1β rs1143623 C allele with the risk for Parkinson's disease (OR = 0.59; 95%CI = 0.38-0.92, p = 0.021). CAT rs1001179 A allele was significantly associated with peripheral edema (OR = 0.32; 95%CI = 0.15-0.68; p = 0.003). Other associations observed were only nominally significant after adjustments: NOS1 rs2682826 A allele and excessive daytime sleepiness and sleep attacks (OR = 1.75; 95%CI = 1.00-3.06, p = 0.048), SOD2 rs4880 T allele and nausea/vomiting (OR = 0.49, 95%CI = 0.25-0.94; p = 0.031), IL1β rs1143623 C allele and orthostatic hypotension (OR = 0.57, 95%CI = 0.32-1.00, p = 0.050), and NOS1 rs2682826 A allele and impulse control disorders (OR = 2.59; 95%CI = 1.09-6.19; p = 0.032). We did not find any associations between selected polymorphisms and motor adverse events. Conclusions: Apart from some nominally significant associations, one significant association between CAT genetic variability and peripheral edema was observed as well. Therefore, the results of our study suggest some links between genetic variability in inflammation- and oxidative stress-related pathways and non-motor adverse events of dopaminergic treatment. However, the investigated polymorphisms do not play a major role in the occurrence of the disease and the adverse events of dopaminergic treatment.</ce:para></abstract></dc:description><link href="https://api.elsevier.com/content/abstract/scopus_id/85062329074" rel="self"/><link href="https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&amp;scp=85062329074&amp;origin=inward" rel="scopus"/><link href="https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&amp;scp=85062329074&amp;origin=inward" rel="scopus-citedby"/></coredata><affiliation id="60021802" href="https://api.elsevier.com/content/affiliation/affiliation_id/60021802"><affilname>University of Ljubljana Faculty of Medicine</affilname><affiliation-city>Ljubljana</affiliation-city><affiliation-country>Slovenia</affiliation-country></affiliation><affiliation id="60021479" href="https://api.elsevier.com/content/affiliation/affiliation_id/60021479"><affilname>Univerzitetni Klinični Center Ljubljana</affilname><affiliation-city>Ljubljana</affiliation-city><affiliation-country>Slovenia</affiliation-country></affiliation><authors><author seq="1" auid="57193522851"><ce:initials>S.</ce:initials><ce:indexed-name>Redensek S.</ce:indexed-name><ce:surname>Redenšek</ce:surname><ce:given-name>Sara</ce:given-name><preferred-name><ce:initials>S.</ce:initials><ce:indexed-name>Redenšek S.</ce:indexed-name><ce:surname>Redenšek</ce:surname><ce:given-name>Sara</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/57193522851</author-url><affiliation id="60021802" href="https://api.elsevier.com/content/affiliation/affiliation_id/60021802"/></author><author seq="2" auid="6503981050"><ce:initials>D.</ce:initials><ce:indexed-name>Flisar D.</ce:indexed-name><ce:surname>Flisar</ce:surname><ce:given-name>Dušan</ce:given-name><preferred-name><ce:initials>D.</ce:initials><ce:indexed-name>Flisar D.</ce:indexed-name><ce:surname>Flisar</ce:surname><ce:given-name>Dušan</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/6503981050</author-url><affiliation id="60021479" href="https://api.elsevier.com/content/affiliation/affiliation_id/60021479"/></author><author seq="3" auid="36652889900"><ce:initials>M.</ce:initials><ce:indexed-name>Kojovic M.</ce:indexed-name><ce:surname>Kojović</ce:surname><ce:given-name>Maja</ce:given-name><preferred-name><ce:initials>M.</ce:initials><ce:indexed-name>Kojović M.</ce:indexed-name><ce:surname>Kojović</ce:surname><ce:given-name>Maja</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/36652889900</author-url><affiliation id="60021479" href="https://api.elsevier.com/content/affiliation/affiliation_id/60021479"/></author><author seq="4" auid="36544238400"><ce:initials>M.G.</ce:initials><ce:indexed-name>Kramberger M.G.</ce:indexed-name><ce:surname>Kramberger</ce:surname><ce:given-name>Milica Gregorič</ce:given-name><preferred-name><ce:initials>M.G.</ce:initials><ce:indexed-name>Kramberger M.</ce:indexed-name><ce:surname>Kramberger</ce:surname><ce:given-name>Milica Gregorič</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/36544238400</author-url><affiliation id="60021479" href="https://api.elsevier.com/content/affiliation/affiliation_id/60021479"/></author><author seq="5" auid="36542322400"><ce:initials>D.</ce:initials><ce:indexed-name>Georgiev D.</ce:indexed-name><ce:surname>Georgiev</ce:surname><ce:given-name>Dejan</ce:given-name><preferred-name><ce:initials>D.</ce:initials><ce:indexed-name>Georgiev D.</ce:indexed-name><ce:surname>Georgiev</ce:surname><ce:given-name>Dejan</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/36542322400</author-url><affiliation id="60021479" href="https://api.elsevier.com/content/affiliation/affiliation_id/60021479"/></author><author seq="6" auid="6603412901"><ce:initials>Z.</ce:initials><ce:indexed-name>Pirtosek Z.</ce:indexed-name><ce:surname>Pirtošek</ce:surname><ce:given-name>Zvezdan</ce:given-name><preferred-name><ce:initials>Z.</ce:initials><ce:indexed-name>Pirtošek Z.</ce:indexed-name><ce:surname>Pirtošek</ce:surname><ce:given-name>Zvezdan</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/6603412901</author-url><affiliation id="60021479" href="https://api.elsevier.com/content/affiliation/affiliation_id/60021479"/></author><author seq="7" auid="7003908826"><ce:initials>M.</ce:initials><ce:indexed-name>Trost M.</ce:indexed-name><ce:surname>Trošt</ce:surname><ce:given-name>Maja</ce:given-name><preferred-name><ce:initials>M.</ce:initials><ce:indexed-name>Trošt M.</ce:indexed-name><ce:surname>Trošt</ce:surname><ce:given-name>Maja</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/7003908826</author-url><affiliation id="60021479" href="https://api.elsevier.com/content/affiliation/affiliation_id/60021479"/></author><author seq="8" auid="6602823313"><ce:initials>V.</ce:initials><ce:indexed-name>Dolzan V.</ce:indexed-name><ce:surname>Dolžan</ce:surname><ce:given-name>Vita</ce:given-name><preferred-name><ce:initials>V.</ce:initials><ce:indexed-name>Dolžan V.</ce:indexed-name><ce:surname>Dolžan</ce:surname><ce:given-name>Vita</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/6602823313</author-url><affiliation id="60021802" href="https://api.elsevier.com/content/affiliation/affiliation_id/60021802"/></author></authors><language xml:lang="eng"/><authkeywords><author-keyword>Adverse events</author-keyword><author-keyword>Inflammation</author-keyword><author-keyword>Oxidative stress</author-keyword><author-keyword>Parkinson's disease</author-keyword><author-keyword>Polymorphism</author-keyword><author-keyword>Susceptibility</author-keyword></authkeywords><idxterms><mainterm weight="b" candidate="n">Aged</mainterm><mainterm weight="b" candidate="n">Antiparkinson Agents</mainterm><mainterm weight="b" candidate="n">Female</mainterm><mainterm weight="b" candidate="n">Genetic Predisposition to Disease</mainterm><mainterm weight="b" candidate="n">Genotype</mainterm><mainterm weight="b" candidate="n">Humans</mainterm><mainterm weight="b" candidate="n">Inflammation</mainterm><mainterm weight="b" candidate="n">Levodopa</mainterm><mainterm weight="b" candidate="n">Male</mainterm><mainterm weight="b" candidate="n">Oxidative Stress</mainterm><mainterm weight="b" candidate="n">Parkinson Disease</mainterm><mainterm weight="b" candidate="n">Polymorphism, Single Nucleotide</mainterm></idxterms><subject-areas><subject-area code="2800" abbrev="NEUR">Neuroscience (all)</subject-area><subject-area code="2403" abbrev="IMMU">Immunology</subject-area><subject-area code="2808" abbrev="NEUR">Neurology</subject-area><subject-area code="2804" abbrev="NEUR">Cellular and Molecular Neuroscience</subject-area></subject-areas><item xmlns=""><xocs:meta><xocs:funding-list has-funding-info="1" pui-match="primary"><xocs:funding-addon-generated-timestamp>2019-03-13T22:23:15.822Z</xocs:funding-addon-generated-timestamp><xocs:funding-addon-type>http://vtw.elsevier.com/data/voc/AddOnTypes/50.7/nlp</xocs:funding-addon-type><xocs:funding><xocs:funding-agency-matched-string>Slovenian Research Agency</xocs:funding-agency-matched-string><xocs:funding-id>P1–0170</xocs:funding-id><xocs:funding-id>ARRS</xocs:funding-id><xocs:funding-agency-acronym>ARRS</xocs:funding-agency-acronym><xocs:funding-agency>Javna Agencija za Raziskovalno Dejavnost RS</xocs:funding-agency><xocs:funding-agency-id>http://data.elsevier.com/vocabulary/SciValFunders/501100004329</xocs:funding-agency-id><xocs:funding-agency-country>http://sws.geonames.org/3190538/</xocs:funding-agency-country></xocs:funding><xocs:funding-text>This study was funded by the Slovenian Research Agency (ARRS), grant number P1–0170 and grant for young researchers (SR).</xocs:funding-text></xocs:funding-list></xocs:meta><ait:process-info><ait:date-delivered day="05" month="07" timestamp="2019-07-05T11:19:06.000006-04:00" year="2019"/><ait:date-sort day="27" month="02" year="2019"/><ait:status stage="S300" state="update" type="core"/></ait:process-info><bibrecord><item-info><copyright type="Elsevier">Copyright 2019 Elsevier B.V., All rights reserved.</copyright><itemidlist><ce:doi>10.1186/s12974-019-1439-y</ce:doi><itemid idtype="PUI">626538981</itemid><itemid idtype="CAR-ID">915928033</itemid><itemid idtype="EMBASE">20190145046</itemid><itemid idtype="MEDL">30813952</itemid><itemid idtype="REAXYSCAR">20190377803</itemid><itemid idtype="RMC">2019062641</itemid><itemid idtype="SCOPUS">20190633190</itemid><itemid idtype="SCP">85062329074</itemid><itemid idtype="SGR">85062329074</itemid><itemid idtype="PUIsecondary">626621702</itemid><itemid idtype="OSIN">78406199</itemid></itemidlist><history><date-created day="08" month="03" timestamp="BST 08:44:35" year="2019"/></history><dbcollection>EMBASE</dbcollection><dbcollection>MEDL</dbcollection><dbcollection>REAXYSCAR</dbcollection><dbcollection>RMC</dbcollection><dbcollection>SCOPUS</dbcollection><dbcollection>Scopusbase</dbcollection><external-source>In-Process</external-source></item-info><head><citation-info><citation-type code="ar"/><citation-language xml:lang="eng" language="English"/><abstract-language xml:lang="eng" language="English"/><author-keywords><author-keyword xml:lang="eng">Adverse events</author-keyword><author-keyword xml:lang="eng">Inflammation</author-keyword><author-keyword xml:lang="eng">Oxidative stress</author-keyword><author-keyword xml:lang="eng">Parkinson's disease</author-keyword><author-keyword xml:lang="eng">Polymorphism</author-keyword><author-keyword xml:lang="eng">Susceptibility</author-keyword></author-keywords></citation-info><citation-title><titletext original="y" xml:lang="eng" language="English">Genetic variability of inflammation and oxidative stress genes does not play a major role in the occurrence of adverse events of dopaminergic treatment in Parkinson's disease</titletext></citation-title><author-group><author auid="57193522851" seq="1" type="auth"><ce:initials>S.</ce:initials><ce:indexed-name>Redensek S.</ce:indexed-name><ce:surname>Redenšek</ce:surname><ce:given-name>Sara</ce:given-name><preferred-name><ce:initials>S.</ce:initials><ce:indexed-name>Redenšek S.</ce:indexed-name><ce:surname>Redenšek</ce:surname><ce:given-name>Sara</ce:given-name></preferred-name></author><author auid="6602823313" orcid="0000-0001-6707-6649" seq="8" type="auth"><ce:initials>V.</ce:initials><ce:indexed-name>Dolzan V.</ce:indexed-name><ce:surname>Dolžan</ce:surname><ce:given-name>Vita</ce:given-name><preferred-name><ce:initials>V.</ce:initials><ce:indexed-name>Dolžan V.</ce:indexed-name><ce:surname>Dolžan</ce:surname><ce:given-name>Vita</ce:given-name></preferred-name></author><affiliation afid="60021802" country="svn" dptid="118365231"><organization>Pharmacogenetics Laboratory</organization><organization>Institute of Biochemistry</organization><organization>Faculty of Medicine</organization><organization>University of Ljubljana</organization><address-part>Vrazov trg 2</address-part><city>Ljubljana</city><postal-code>1000</postal-code><affiliation-id afid="60021802" dptid="118365231"/><affiliation-id afid="60031106"/><country>Slovenia</country></affiliation></author-group><author-group><author auid="6503981050" seq="2" type="auth"><ce:initials>D.</ce:initials><ce:indexed-name>Flisar D.</ce:indexed-name><ce:surname>Flisar</ce:surname><ce:given-name>Dušan</ce:given-name><preferred-name><ce:initials>D.</ce:initials><ce:indexed-name>Flisar D.</ce:indexed-name><ce:surname>Flisar</ce:surname><ce:given-name>Dušan</ce:given-name></preferred-name></author><author auid="36652889900" seq="3" type="auth"><ce:initials>M.</ce:initials><ce:indexed-name>Kojovic M.</ce:indexed-name><ce:surname>Kojović</ce:surname><ce:given-name>Maja</ce:given-name><preferred-name><ce:initials>M.</ce:initials><ce:indexed-name>Kojović M.</ce:indexed-name><ce:surname>Kojović</ce:surname><ce:given-name>Maja</ce:given-name></preferred-name></author><author auid="36544238400" seq="4" type="auth"><ce:initials>M.G.</ce:initials><ce:indexed-name>Kramberger M.G.</ce:indexed-name><ce:surname>Kramberger</ce:surname><ce:given-name>Milica Gregorič</ce:given-name><preferred-name><ce:initials>M.G.</ce:initials><ce:indexed-name>Kramberger M.</ce:indexed-name><ce:surname>Kramberger</ce:surname><ce:given-name>Milica Gregorič</ce:given-name></preferred-name></author><author auid="36542322400" seq="5" type="auth"><ce:initials>D.</ce:initials><ce:indexed-name>Georgiev D.</ce:indexed-name><ce:surname>Georgiev</ce:surname><ce:given-name>Dejan</ce:given-name><preferred-name><ce:initials>D.</ce:initials><ce:indexed-name>Georgiev D.</ce:indexed-name><ce:surname>Georgiev</ce:surname><ce:given-name>Dejan</ce:given-name></preferred-name></author><author auid="6603412901" seq="6" type="auth"><ce:initials>Z.</ce:initials><ce:indexed-name>Pirtosek Z.</ce:indexed-name><ce:surname>Pirtošek</ce:surname><ce:given-name>Zvezdan</ce:given-name><preferred-name><ce:initials>Z.</ce:initials><ce:indexed-name>Pirtošek Z.</ce:indexed-name><ce:surname>Pirtošek</ce:surname><ce:given-name>Zvezdan</ce:given-name></preferred-name></author><author auid="7003908826" seq="7" type="auth"><ce:initials>M.</ce:initials><ce:indexed-name>Trost M.</ce:indexed-name><ce:surname>Trošt</ce:surname><ce:given-name>Maja</ce:given-name><preferred-name><ce:initials>M.</ce:initials><ce:indexed-name>Trošt M.</ce:indexed-name><ce:surname>Trošt</ce:surname><ce:given-name>Maja</ce:given-name></preferred-name></author><affiliation afid="60021479" country="svn" dptid="113072952"><organization>Department of Neurology</organization><organization>University Medical Centre Ljubljana</organization><address-part>Zaloška cesta 2</address-part><city>Ljubljana</city><postal-code>1000</postal-code><affiliation-id afid="60021479" dptid="113072952"/><country>Slovenia</country></affiliation></author-group><correspondence><person><ce:initials>V.</ce:initials><ce:indexed-name>Dolzan V.</ce:indexed-name><ce:surname>Dolžan</ce:surname><ce:given-name>Vita</ce:given-name></person><affiliation country="svn"><organization>Pharmacogenetics Laboratory</organization><organization>Institute of Biochemistry</organization><organization>Faculty of Medicine</organization><organization>University of Ljubljana</organization><address-part>Vrazov trg 2</address-part><city>Ljubljana</city><postal-code>1000</postal-code><country>Slovenia</country></affiliation></correspondence><abstracts><abstract original="y" xml:lang="eng"><publishercopyright>© 2019 The Author(s).</publishercopyright><ce:para>Background: Inflammation and oxidative stress are recognized as important contributors to Parkinson's disease pathogenesis. As such, genetic variability in these pathways could have a role in susceptibility for the disease as well as in the treatment outcome. Dopaminergic treatment is effective in management of motor symptoms, but poses a risk for motor and non-motor adverse events. Our aim was to evaluate the impact of selected single-nucleotide polymorphisms in genes involved in inflammation and oxidative stress on Parkinson's disease susceptibility and the occurrence of adverse events of dopaminergic treatment. Methods: In total, 224 patients were enrolled, and their demographic and clinical data on the disease course were collected. Furthermore, a control group of 146 healthy Slovenian blood donors were included for Parkinson's disease' risk evaluation. Peripheral blood was obtained for DNA isolation. Genotyping was performed for NLRP3 rs35829419, CARD8 rs2043211, IL1β rs16944, IL1β rs1143623, IL6 rs1800795, CAT rs1001179, CAT rs10836235, SOD2 rs4880, NOS1 rs2293054, NOS1 rs2682826, TNF-α rs1800629, and GPX1 rs1050450. Logistic regression was used for analysis of possible associations. Results: We observed a nominally significant association of the IL1β rs1143623 C allele with the risk for Parkinson's disease (OR = 0.59; 95%CI = 0.38-0.92, p = 0.021). CAT rs1001179 A allele was significantly associated with peripheral edema (OR = 0.32; 95%CI = 0.15-0.68; p = 0.003). Other associations observed were only nominally significant after adjustments: NOS1 rs2682826 A allele and excessive daytime sleepiness and sleep attacks (OR = 1.75; 95%CI = 1.00-3.06, p = 0.048), SOD2 rs4880 T allele and nausea/vomiting (OR = 0.49, 95%CI = 0.25-0.94; p = 0.031), IL1β rs1143623 C allele and orthostatic hypotension (OR = 0.57, 95%CI = 0.32-1.00, p = 0.050), and NOS1 rs2682826 A allele and impulse control disorders (OR = 2.59; 95%CI = 1.09-6.19; p = 0.032). We did not find any associations between selected polymorphisms and motor adverse events. Conclusions: Apart from some nominally significant associations, one significant association between CAT genetic variability and peripheral edema was observed as well. Therefore, the results of our study suggest some links between genetic variability in inflammation- and oxidative stress-related pathways and non-motor adverse events of dopaminergic treatment. However, the investigated polymorphisms do not play a major role in the occurrence of the disease and the adverse events of dopaminergic treatment.</ce:para></abstract></abstracts><source country="gbr" srcid="50032" type="j"><sourcetitle>Journal of Neuroinflammation</sourcetitle><sourcetitle-abbrev>J. Neuroinflamm.</sourcetitle-abbrev><translated-sourcetitle xml:lang="eng">Journal of Neuroinflammation</translated-sourcetitle><issn type="electronic">17422094</issn><volisspag><voliss issue="1" volume="16"/></volisspag><article-number>50</article-number><publicationyear first="2019"/><publicationdate><year>2019</year><month>02</month><day>27</day><date-text xfab-added="true">27 February 2019</date-text></publicationdate><website><ce:e-address type="email">http://www.jneuroinflammation.com/home/</ce:e-address></website><publisher><publishername>BioMed Central Ltd.</publishername><ce:e-address type="email">info@biomedcentral.com</ce:e-address></publisher></source><enhancement><classificationgroup><classifications type="EMCLASS"><classification>                                                                  <classification-code>22</classification-code>                                                                  <classification-description>Human Genetics</classification-description>                                                              </classification><classification>                                                                  <classification-code>37</classification-code>                                                                  <classification-description>Drug Literature Index</classification-description>                                                              </classification><classification>                                                                  <classification-code>38</classification-code>                                                                  <classification-description>Adverse Reactions Titles</classification-description>                                                              </classification><classification>                                                                  <classification-code>8</classification-code>                                                                  <classification-description>Neurology and Neurosurgery</classification-description>                                                              </classification></classifications><classifications type="ASJC"><classification>2800</classification><classification>2403</classification><classification>2808</classification><classification>2804</classification></classifications><classifications type="SUBJABBR"><classification>NEUR</classification><classification>IMMU</classification></classifications></classificationgroup><chemicalgroup><chemicals source="esbd"><chemical><chemical-name>catalase</chemical-name><cas-registry-number>9001-05-2</cas-registry-number><enzyme-commission-number>EC 1.11.1.6</enzyme-commission-number></chemical><chemical><chemical-name>levodopa</chemical-name><cas-registry-number>59-92-7</cas-registry-number></chemical><chemical><chemical-name>neuronal nitric oxide synthase</chemical-name><cas-registry-number>506430-87-1</cas-registry-number></chemical></chemicals><chemicals source="nlm"><chemical><chemical-name>Antiparkinson Agents</chemical-name></chemical><chemical><chemical-name>Levodopa</chemical-name></chemical></chemicals></chemicalgroup></enhancement></head><tail><bibliography refcount="79"><reference id="1"><ref-info><ref-title><ref-titletext>Parkinson disease</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">85016139358</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>W.</ce:initials><ce:indexed-name>Poewe W.</ce:indexed-name><ce:surname>Poewe</ce:surname></author><author seq="2"><ce:initials>K.</ce:initials><ce:indexed-name>Seppi K.</ce:indexed-name><ce:surname>Seppi</ce:surname></author><author seq="3"><ce:initials>C.M.</ce:initials><ce:indexed-name>Tanner C.M.</ce:indexed-name><ce:surname>Tanner</ce:surname></author><author seq="4"><ce:initials>G.M.</ce:initials><ce:indexed-name>Halliday G.M.</ce:indexed-name><ce:surname>Halliday</ce:surname></author><author seq="5"><ce:initials>P.</ce:initials><ce:indexed-name>Brundin P.</ce:indexed-name><ce:surname>Brundin</ce:surname></author><author seq="6"><ce:initials>J.</ce:initials><ce:indexed-name>Volkmann J.</ce:indexed-name><ce:surname>Volkmann</ce:surname></author><author seq="7"><ce:initials>A.E.</ce:initials><ce:indexed-name>Schrag A.E.</ce:indexed-name><ce:surname>Schrag</ce:surname></author><author seq="8"><ce:initials>A.E.</ce:initials><ce:indexed-name>Lang A.E.</ce:indexed-name><ce:surname>Lang</ce:surname></author></ref-authors><ref-sourcetitle>Nat Rev Dis Primers</ref-sourcetitle><ref-publicationyear first="2017"/><ref-volisspag><voliss volume="3"/><pagerange first="13"/></ref-volisspag></ref-info><ref-fulltext>Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, Schrag AE, Lang AE. Parkinson disease. Nat Rev Dis Primers. 2017;3:13.</ref-fulltext></reference><reference id="2"><ref-info><ref-title><ref-titletext>The role of inflammation in sporadic and familial Parkinson's disease</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84887083013</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>M.</ce:initials><ce:indexed-name>Deleidi M.</ce:indexed-name><ce:surname>Deleidi</ce:surname></author><author seq="2"><ce:initials>T.</ce:initials><ce:indexed-name>Gasser T.</ce:indexed-name><ce:surname>Gasser</ce:surname></author></ref-authors><ref-sourcetitle>Cell Mol Life Sci</ref-sourcetitle><ref-publicationyear first="2013"/><ref-volisspag><voliss volume="70"/><pagerange first="4259" last="4273"/></ref-volisspag><ref-text>1:CAS:528:DC%2BC3sXhs1OqsL3P 23665870</ref-text></ref-info><ref-fulltext>Deleidi M, Gasser T. The role of inflammation in sporadic and familial Parkinson's disease. Cell Mol Life Sci. 2013;70:4259-73.</ref-fulltext></reference><reference id="3"><ref-info><ref-title><ref-titletext>Genetic determinants of Parkinson's disease: Can they help to stratify the patients based on the underlying molecular defect?</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">85014542359</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>S.</ce:initials><ce:indexed-name>Redensek S.</ce:indexed-name><ce:surname>Redenšek</ce:surname></author><author seq="2"><ce:initials>M.</ce:initials><ce:indexed-name>Trost M.</ce:indexed-name><ce:surname>Trošt</ce:surname></author><author seq="3"><ce:initials>V.</ce:initials><ce:indexed-name>Dolzan V.</ce:indexed-name><ce:surname>Dolžan</ce:surname></author></ref-authors><ref-sourcetitle>Front Aging Neurosci.</ref-sourcetitle><ref-publicationyear first="2017"/><ref-volisspag><voliss volume="9"/><pagerange first="1" last="17"/></ref-volisspag></ref-info><ref-fulltext>Redenšek S, Trošt M, Dolžan V. Genetic determinants of Parkinson's disease: can they help to stratify the patients based on the underlying molecular defect? Front Aging Neurosci. 2017;9:1-17.</ref-fulltext></reference><reference id="4"><ref-info><ref-title><ref-titletext>Parkinson's disease</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84940956493</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>L.V.</ce:initials><ce:indexed-name>Kalia L.V.</ce:indexed-name><ce:surname>Kalia</ce:surname></author><author seq="2"><ce:initials>A.E.</ce:initials><ce:indexed-name>Lang A.E.</ce:indexed-name><ce:surname>Lang</ce:surname></author></ref-authors><ref-sourcetitle>Lancet</ref-sourcetitle><ref-publicationyear first="2015"/><ref-volisspag><voliss volume="386"/><pagerange first="896" last="912"/></ref-volisspag><ref-text>1:CAS:528:DC%2BC2MXmsl2rtb4%3D 25904081</ref-text></ref-info><ref-fulltext>Kalia LV, Lang AE. Parkinson's disease. Lancet. 2015;386:896-912.</ref-fulltext></reference><reference id="5"><ref-info><ref-title><ref-titletext>Inflammatory response in Parkinson's disease (review)</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84907209549</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>J.</ce:initials><ce:indexed-name>Yan J.</ce:indexed-name><ce:surname>Yan</ce:surname></author><author seq="2"><ce:initials>Q.</ce:initials><ce:indexed-name>Fu Q.</ce:indexed-name><ce:surname>Fu</ce:surname></author><author seq="3"><ce:initials>L.</ce:initials><ce:indexed-name>Cheng L.</ce:indexed-name><ce:surname>Cheng</ce:surname></author><author seq="4"><ce:initials>M.</ce:initials><ce:indexed-name>Zhai M.</ce:indexed-name><ce:surname>Zhai</ce:surname></author><author seq="5"><ce:initials>W.</ce:initials><ce:indexed-name>Wu W.</ce:indexed-name><ce:surname>Wu</ce:surname></author><author seq="6"><ce:initials>L.</ce:initials><ce:indexed-name>Huang L.</ce:indexed-name><ce:surname>Huang</ce:surname></author><author seq="7"><ce:initials>G.</ce:initials><ce:indexed-name>Du G.</ce:indexed-name><ce:surname>Du</ce:surname></author></ref-authors><ref-sourcetitle>Mol Med Rep</ref-sourcetitle><ref-publicationyear first="2014"/><ref-volisspag><voliss volume="10"/><pagerange first="2223" last="2233"/></ref-volisspag><ref-text>1:CAS:528:DC%2BC2cXhvFOhsrfN 25215472</ref-text></ref-info><ref-fulltext>Yan J, Fu Q, Cheng L, Zhai M, Wu W, Huang L, Du G. Inflammatory response in Parkinson's disease (review). Mol Med Rep. 2014;10:2223-33.</ref-fulltext></reference><reference id="6"><ref-info><ref-title><ref-titletext>Neurodegeneration and inflammation in Parkinson's disease</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84858650685</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>S.</ce:initials><ce:indexed-name>Phani S.</ce:indexed-name><ce:surname>Phani</ce:surname></author><author seq="2"><ce:initials>J.D.</ce:initials><ce:indexed-name>Loike J.D.</ce:indexed-name><ce:surname>Loike</ce:surname></author><author seq="3"><ce:initials>S.</ce:initials><ce:indexed-name>Przedborski S.</ce:indexed-name><ce:surname>Przedborski</ce:surname></author></ref-authors><ref-sourcetitle>Parkinsonism Relat Disord</ref-sourcetitle><ref-publicationyear first="2012"/><ref-volisspag><voliss volume="18"/><pagerange first="70064" last="70065"/></ref-volisspag></ref-info><ref-fulltext>Phani S, Loike JD, Przedborski S. Neurodegeneration and inflammation in Parkinson's disease. Parkinsonism Relat Disord. 2012;18:70064-5.</ref-fulltext></reference><reference id="7"><ref-info><ref-title><ref-titletext>Cerebrospinal fluid biomarkers for Parkinson's disease - A systematic review</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84961276030</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>A.D.</ce:initials><ce:indexed-name>Andersen A.D.</ce:indexed-name><ce:surname>Andersen</ce:surname></author><author seq="2"><ce:initials>M.</ce:initials><ce:indexed-name>Binzer M.</ce:indexed-name><ce:surname>Binzer</ce:surname></author><author seq="3"><ce:initials>E.</ce:initials><ce:indexed-name>Stenager E.</ce:indexed-name><ce:surname>Stenager</ce:surname></author><author seq="4"><ce:initials>J.B.</ce:initials><ce:indexed-name>Gramsbergen J.B.</ce:indexed-name><ce:surname>Gramsbergen</ce:surname></author></ref-authors><ref-sourcetitle>Acta Neurol Scand</ref-sourcetitle><ref-publicationyear first="2017"/><ref-volisspag><voliss volume="135"/><pagerange first="34" last="56"/></ref-volisspag><ref-text>1:CAS:528:DC%2BC28XitVWqtLbI 26991855</ref-text></ref-info><ref-fulltext>Andersen AD, Binzer M, Stenager E, Gramsbergen JB. Cerebrospinal fluid biomarkers for Parkinson's disease - a systematic review. Acta Neurol Scand. 2017;135:34-56.</ref-fulltext></reference><reference id="8"><ref-info><ref-title><ref-titletext>Triggering of inflammasome by aggregated alpha-synuclein, an inflammatory response in synucleinopathies</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84873123076</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>G.</ce:initials><ce:indexed-name>Codolo G.</ce:indexed-name><ce:surname>Codolo</ce:surname></author><author seq="2"><ce:initials>N.</ce:initials><ce:indexed-name>Plotegher N.</ce:indexed-name><ce:surname>Plotegher</ce:surname></author><author seq="3"><ce:initials>T.</ce:initials><ce:indexed-name>Pozzobon T.</ce:indexed-name><ce:surname>Pozzobon</ce:surname></author><author seq="4"><ce:initials>M.</ce:initials><ce:indexed-name>Brucale M.</ce:indexed-name><ce:surname>Brucale</ce:surname></author><author seq="5"><ce:initials>I.</ce:initials><ce:indexed-name>Tessari I.</ce:indexed-name><ce:surname>Tessari</ce:surname></author><author seq="6"><ce:initials>L.</ce:initials><ce:indexed-name>Bubacco L.</ce:indexed-name><ce:surname>Bubacco</ce:surname></author><author seq="7"><ce:initials>M.</ce:initials><ce:indexed-name>De Bernard M.</ce:indexed-name><ce:surname>De Bernard</ce:surname></author></ref-authors><ref-sourcetitle>PLoS One</ref-sourcetitle><ref-publicationyear first="2013"/><ref-volisspag><voliss volume="8"/><pagerange first="31"/></ref-volisspag></ref-info><ref-fulltext>Codolo G, Plotegher N, Pozzobon T, Brucale M, Tessari I, Bubacco L, de Bernard M. Triggering of inflammasome by aggregated alpha-synuclein, an inflammatory response in synucleinopathies. PLoS One. 2013;8:31.</ref-fulltext></reference><reference id="9"><ref-info><ref-title><ref-titletext>A pathway-based analysis provides additional support for an immune-related genetic susceptibility to Parkinson's disease (vol 22, pg 1039, 2013)</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84903845742</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>P.</ce:initials><ce:indexed-name>Holmans P.</ce:indexed-name><ce:surname>Holmans</ce:surname></author><author seq="2"><ce:initials>V.</ce:initials><ce:indexed-name>Moskvina V.</ce:indexed-name><ce:surname>Moskvina</ce:surname></author><author seq="3"><ce:initials>L.</ce:initials><ce:indexed-name>Jones L.</ce:indexed-name><ce:surname>Jones</ce:surname></author><author seq="4"><ce:initials>M.</ce:initials><ce:indexed-name>Sharma M.</ce:indexed-name><ce:surname>Sharma</ce:surname></author><author seq="5"><ce:initials>A.</ce:initials><ce:indexed-name>Vedernikov A.</ce:indexed-name><ce:surname>Vedernikov</ce:surname></author><author seq="6"><ce:initials>F.</ce:initials><ce:indexed-name>Buchel F.</ce:indexed-name><ce:surname>Buchel</ce:surname></author><author seq="7"><ce:initials>M.</ce:initials><ce:indexed-name>Saad M.</ce:indexed-name><ce:surname>Saad</ce:surname></author><author seq="8"><ce:initials>J.M.</ce:initials><ce:indexed-name>Bras J.M.</ce:indexed-name><ce:surname>Bras</ce:surname></author><author seq="9"><ce:initials>F.</ce:initials><ce:indexed-name>Bettella F.</ce:indexed-name><ce:surname>Bettella</ce:surname></author><author seq="10"><ce:initials>N.</ce:initials><ce:indexed-name>Nicolaou N.</ce:indexed-name><ce:surname>Nicolaou</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Hum Mol Genet</ref-sourcetitle><ref-publicationyear first="2014"/><ref-volisspag><voliss volume="23"/><pagerange first="562"/></ref-volisspag><ref-text>1:CAS:528:DC%2BC3sXhvFOntrfN</ref-text></ref-info><ref-fulltext>Holmans P, Moskvina V, Jones L, Sharma M, Vedernikov A, Buchel F, Saad M, Bras JM, Bettella F, Nicolaou N, et al. A pathway-based analysis provides additional support for an immune-related genetic susceptibility to Parkinson's disease (vol 22, pg 1039, 2013). Hum Mol Genet. 2014;23:562.</ref-fulltext></reference><reference id="10"><ref-info><ref-title><ref-titletext>Microglial activation in Parkinson's disease using [(18)F]-FEPPA</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">85009250562</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>C.</ce:initials><ce:indexed-name>Ghadery C.</ce:indexed-name><ce:surname>Ghadery</ce:surname></author><author seq="2"><ce:initials>Y.</ce:initials><ce:indexed-name>Koshimori Y.</ce:indexed-name><ce:surname>Koshimori</ce:surname></author><author seq="3"><ce:initials>S.</ce:initials><ce:indexed-name>Coakeley S.</ce:indexed-name><ce:surname>Coakeley</ce:surname></author><author seq="4"><ce:initials>M.</ce:initials><ce:indexed-name>Harris M.</ce:indexed-name><ce:surname>Harris</ce:surname></author><author seq="5"><ce:initials>P.</ce:initials><ce:indexed-name>Rusjan P.</ce:indexed-name><ce:surname>Rusjan</ce:surname></author><author seq="6"><ce:initials>J.</ce:initials><ce:indexed-name>Kim J.</ce:indexed-name><ce:surname>Kim</ce:surname></author><author seq="7"><ce:initials>S.</ce:initials><ce:indexed-name>Houle S.</ce:indexed-name><ce:surname>Houle</ce:surname></author><author seq="8"><ce:initials>A.P.</ce:initials><ce:indexed-name>Strafella A.P.</ce:indexed-name><ce:surname>Strafella</ce:surname></author></ref-authors><ref-sourcetitle>J Neuroinflammation</ref-sourcetitle><ref-publicationyear first="2017"/><ref-volisspag><voliss volume="14"/><pagerange first="16" last="0778"/></ref-volisspag></ref-info><ref-fulltext>Ghadery C, Koshimori Y, Coakeley S, Harris M, Rusjan P, Kim J, Houle S, Strafella AP. Microglial activation in Parkinson's disease using [(18)F]-FEPPA. J Neuroinflammation. 2017;14:016-0778.</ref-fulltext></reference><reference id="11"><ref-info><ref-title><ref-titletext>Neuroinflammation in the living brain of Parkinson's disease</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">71849087424</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>Y.</ce:initials><ce:indexed-name>Ouchi Y.</ce:indexed-name><ce:surname>Ouchi</ce:surname></author><author seq="2"><ce:initials>S.</ce:initials><ce:indexed-name>Yagi S.</ce:indexed-name><ce:surname>Yagi</ce:surname></author><author seq="3"><ce:initials>M.</ce:initials><ce:indexed-name>Yokokura M.</ce:indexed-name><ce:surname>Yokokura</ce:surname></author><author seq="4"><ce:initials>M.</ce:initials><ce:indexed-name>Sakamoto M.</ce:indexed-name><ce:surname>Sakamoto</ce:surname></author></ref-authors><ref-sourcetitle>Parkinsonism Relat Disord</ref-sourcetitle><ref-publicationyear first="2009"/><ref-volisspag><voliss volume="15"/><pagerange first="70814"/></ref-volisspag></ref-info><ref-fulltext>Ouchi Y, Yagi S, Yokokura M, Sakamoto M. Neuroinflammation in the living brain of Parkinson's disease. Parkinsonism Relat Disord. 2009;15:70814.</ref-fulltext></reference><reference id="12"><ref-info><ref-title><ref-titletext>In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">30744472146</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>A.</ce:initials><ce:indexed-name>Gerhard A.</ce:indexed-name><ce:surname>Gerhard</ce:surname></author><author seq="2"><ce:initials>N.</ce:initials><ce:indexed-name>Pavese N.</ce:indexed-name><ce:surname>Pavese</ce:surname></author><author seq="3"><ce:initials>G.</ce:initials><ce:indexed-name>Hotton G.</ce:indexed-name><ce:surname>Hotton</ce:surname></author><author seq="4"><ce:initials>F.</ce:initials><ce:indexed-name>Turkheimer F.</ce:indexed-name><ce:surname>Turkheimer</ce:surname></author><author seq="5"><ce:initials>M.</ce:initials><ce:indexed-name>Es M.</ce:indexed-name><ce:surname>Es</ce:surname></author><author seq="6"><ce:initials>A.</ce:initials><ce:indexed-name>Hammers A.</ce:indexed-name><ce:surname>Hammers</ce:surname></author><author seq="7"><ce:initials>K.</ce:initials><ce:indexed-name>Eggert K.</ce:indexed-name><ce:surname>Eggert</ce:surname></author><author seq="8"><ce:initials>W.</ce:initials><ce:indexed-name>Oertel W.</ce:indexed-name><ce:surname>Oertel</ce:surname></author><author seq="9"><ce:initials>R.B.</ce:initials><ce:indexed-name>Banati R.B.</ce:indexed-name><ce:surname>Banati</ce:surname></author><author seq="10"><ce:initials>D.J.</ce:initials><ce:indexed-name>Brooks D.J.</ce:indexed-name><ce:surname>Brooks</ce:surname></author></ref-authors><ref-sourcetitle>Neurobiol Dis</ref-sourcetitle><ref-publicationyear first="2006"/><ref-volisspag><voliss volume="21"/><pagerange first="404" last="412"/></ref-volisspag><ref-text>1:CAS:528:DC%2BD28XmsVGmsg%3D%3D 16182554</ref-text></ref-info><ref-fulltext>Gerhard A, Pavese N, Hotton G, Turkheimer F, Es M, Hammers A, Eggert K, Oertel W, Banati RB, Brooks DJ. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiol Dis. 2006;21:404-12.</ref-fulltext></reference><reference id="13"><ref-info><ref-title><ref-titletext>Inflammatory cytokines and NT-proCNP in Parkinson's disease patients</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84867985183</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>D.</ce:initials><ce:indexed-name>Koziorowski D.</ce:indexed-name><ce:surname>Koziorowski</ce:surname></author><author seq="2"><ce:initials>R.</ce:initials><ce:indexed-name>Tomasiuk R.</ce:indexed-name><ce:surname>Tomasiuk</ce:surname></author><author seq="3"><ce:initials>S.</ce:initials><ce:indexed-name>Szlufik S.</ce:indexed-name><ce:surname>Szlufik</ce:surname></author><author seq="4"><ce:initials>A.</ce:initials><ce:indexed-name>Friedman A.</ce:indexed-name><ce:surname>Friedman</ce:surname></author></ref-authors><ref-sourcetitle>Cytokine</ref-sourcetitle><ref-publicationyear first="2012"/><ref-volisspag><voliss volume="60"/><pagerange first="762" last="766"/></ref-volisspag><ref-text>1:CAS:528:DC%2BC38Xht1emt7%2FJ 22910321</ref-text></ref-info><ref-fulltext>Koziorowski D, Tomasiuk R, Szlufik S, Friedman A. Inflammatory cytokines and NT-proCNP in Parkinson's disease patients. Cytokine. 2012;60:762-6.</ref-fulltext></reference><reference id="14"><ref-info><ref-title><ref-titletext>Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">0028178281</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>M.</ce:initials><ce:indexed-name>Mogi M.</ce:indexed-name><ce:surname>Mogi</ce:surname></author><author seq="2"><ce:initials>M.</ce:initials><ce:indexed-name>Harada M.</ce:indexed-name><ce:surname>Harada</ce:surname></author><author seq="3"><ce:initials>P.</ce:initials><ce:indexed-name>Riederer P.</ce:indexed-name><ce:surname>Riederer</ce:surname></author><author seq="4"><ce:initials>H.</ce:initials><ce:indexed-name>Narabayashi H.</ce:indexed-name><ce:surname>Narabayashi</ce:surname></author><author seq="5"><ce:initials>K.</ce:initials><ce:indexed-name>Fujita K.</ce:indexed-name><ce:surname>Fujita</ce:surname></author><author seq="6"><ce:initials>T.</ce:initials><ce:indexed-name>Nagatsu T.</ce:indexed-name><ce:surname>Nagatsu</ce:surname></author></ref-authors><ref-sourcetitle>Neurosci Lett</ref-sourcetitle><ref-publicationyear first="1994"/><ref-volisspag><voliss volume="165"/><pagerange first="208" last="210"/></ref-volisspag><ref-text>1:CAS:528:DyaK2cXitFCqsbY%3D 8015728</ref-text></ref-info><ref-fulltext>Mogi M, Harada M, Riederer P, Narabayashi H, Fujita K, Nagatsu T. Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci Lett. 1994;165:208-10.</ref-fulltext></reference><reference id="15"><ref-info><ref-title><ref-titletext>Involvement of interferon-gamma in microglial-mediated loss of dopaminergic neurons</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">33947515418</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>M.P.</ce:initials><ce:indexed-name>Mount M.P.</ce:indexed-name><ce:surname>Mount</ce:surname></author><author seq="2"><ce:initials>A.</ce:initials><ce:indexed-name>Lira A.</ce:indexed-name><ce:surname>Lira</ce:surname></author><author seq="3"><ce:initials>D.</ce:initials><ce:indexed-name>Grimes D.</ce:indexed-name><ce:surname>Grimes</ce:surname></author><author seq="4"><ce:initials>P.D.</ce:initials><ce:indexed-name>Smith P.D.</ce:indexed-name><ce:surname>Smith</ce:surname></author><author seq="5"><ce:initials>S.</ce:initials><ce:indexed-name>Faucher S.</ce:indexed-name><ce:surname>Faucher</ce:surname></author><author seq="6"><ce:initials>R.</ce:initials><ce:indexed-name>Slack R.</ce:indexed-name><ce:surname>Slack</ce:surname></author><author seq="7"><ce:initials>H.</ce:initials><ce:indexed-name>Anisman H.</ce:indexed-name><ce:surname>Anisman</ce:surname></author><author seq="8"><ce:initials>S.</ce:initials><ce:indexed-name>Hayley S.</ce:indexed-name><ce:surname>Hayley</ce:surname></author><author seq="9"><ce:initials>D.S.</ce:initials><ce:indexed-name>Park D.S.</ce:indexed-name><ce:surname>Park</ce:surname></author></ref-authors><ref-sourcetitle>J Neurosci</ref-sourcetitle><ref-publicationyear first="2007"/><ref-volisspag><voliss volume="27"/><pagerange first="3328" last="3337"/></ref-volisspag><ref-text>1:CAS:528:DC%2BD2sXktlKntrs%3D 17376993</ref-text></ref-info><ref-fulltext>Mount MP, Lira A, Grimes D, Smith PD, Faucher S, Slack R, Anisman H, Hayley S, Park DS. Involvement of interferon-gamma in microglial-mediated loss of dopaminergic neurons. J Neurosci. 2007;27:3328-37.</ref-fulltext></reference><reference id="16"><ref-info><ref-title><ref-titletext>Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">0029417080</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>D.</ce:initials><ce:indexed-name>Blum-Degen D.</ce:indexed-name><ce:surname>Blum-Degen</ce:surname></author><author seq="2"><ce:initials>T.</ce:initials><ce:indexed-name>Muller T.</ce:indexed-name><ce:surname>Muller</ce:surname></author><author seq="3"><ce:initials>W.</ce:initials><ce:indexed-name>Kuhn W.</ce:indexed-name><ce:surname>Kuhn</ce:surname></author><author seq="4"><ce:initials>M.</ce:initials><ce:indexed-name>Gerlach M.</ce:indexed-name><ce:surname>Gerlach</ce:surname></author><author seq="5"><ce:initials>H.</ce:initials><ce:indexed-name>Przuntek H.</ce:indexed-name><ce:surname>Przuntek</ce:surname></author><author seq="6"><ce:initials>P.</ce:initials><ce:indexed-name>Riederer P.</ce:indexed-name><ce:surname>Riederer</ce:surname></author></ref-authors><ref-sourcetitle>Neurosci Lett</ref-sourcetitle><ref-publicationyear first="1995"/><ref-volisspag><voliss volume="202"/><pagerange first="17" last="20"/></ref-volisspag><ref-text>1:CAS:528:DyaK28XkslOluw%3D%3D 8787820</ref-text></ref-info><ref-fulltext>Blum-Degen D, Muller T, Kuhn W, Gerlach M, Przuntek H, Riederer P. Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neurosci Lett. 1995;202:17-20.</ref-fulltext></reference><reference id="17"><ref-info><ref-title><ref-titletext>Non-motor symptoms in patients with Parkinson's disease - Correlations with inflammatory cytokines in serum</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84867629199</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>D.</ce:initials><ce:indexed-name>Lindqvist D.</ce:indexed-name><ce:surname>Lindqvist</ce:surname></author><author seq="2"><ce:initials>E.</ce:initials><ce:indexed-name>Kaufman E.</ce:indexed-name><ce:surname>Kaufman</ce:surname></author><author seq="3"><ce:initials>L.</ce:initials><ce:indexed-name>Brundin L.</ce:indexed-name><ce:surname>Brundin</ce:surname></author><author seq="4"><ce:initials>S.</ce:initials><ce:indexed-name>Hall S.</ce:indexed-name><ce:surname>Hall</ce:surname></author><author seq="5"><ce:initials>Y.</ce:initials><ce:indexed-name>Surova Y.</ce:indexed-name><ce:surname>Surova</ce:surname></author><author seq="6"><ce:initials>O.</ce:initials><ce:indexed-name>Hansson O.</ce:indexed-name><ce:surname>Hansson</ce:surname></author></ref-authors><ref-sourcetitle>PLoS One</ref-sourcetitle><ref-publicationyear first="2012"/><ref-volisspag><voliss volume="7"/><pagerange first="17"/></ref-volisspag></ref-info><ref-fulltext>Lindqvist D, Kaufman E, Brundin L, Hall S, Surova Y, Hansson O. Non-motor symptoms in patients with Parkinson's disease - correlations with inflammatory cytokines in serum. PLoS One. 2012;7:17.</ref-fulltext></reference><reference id="18"><ref-info><ref-title><ref-titletext>Interleukin-6 levels in cerebrospinal fluid inversely correlate to severity of Parkinson's disease</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">0031857454</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>T.</ce:initials><ce:indexed-name>Muller T.</ce:indexed-name><ce:surname>Muller</ce:surname></author><author seq="2"><ce:initials>D.</ce:initials><ce:indexed-name>Blum-Degen D.</ce:indexed-name><ce:surname>Blum-Degen</ce:surname></author><author seq="3"><ce:initials>H.</ce:initials><ce:indexed-name>Przuntek H.</ce:indexed-name><ce:surname>Przuntek</ce:surname></author><author seq="4"><ce:initials>W.</ce:initials><ce:indexed-name>Kuhn W.</ce:indexed-name><ce:surname>Kuhn</ce:surname></author></ref-authors><ref-sourcetitle>Acta Neurol Scand</ref-sourcetitle><ref-publicationyear first="1998"/><ref-volisspag><voliss volume="98"/><pagerange first="142" last="144"/></ref-volisspag><ref-text>1:CAS:528:DyaK1cXlsFCitrg%3D 9724016</ref-text></ref-info><ref-fulltext>Muller T, Blum-Degen D, Przuntek H, Kuhn W. Interleukin-6 levels in cerebrospinal fluid inversely correlate to severity of Parkinson's disease. Acta Neurol Scand. 1998;98:142-4.</ref-fulltext></reference><reference id="19"><ref-info><ref-title><ref-titletext>Biomarkers for Parkinson's disease: Recent advancement</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">85029682645</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>S.</ce:initials><ce:indexed-name>Lotankar S.</ce:indexed-name><ce:surname>Lotankar</ce:surname></author><author seq="2"><ce:initials>K.S.</ce:initials><ce:indexed-name>Prabhavalkar K.S.</ce:indexed-name><ce:surname>Prabhavalkar</ce:surname></author><author seq="3"><ce:initials>L.K.</ce:initials><ce:indexed-name>Bhatt L.K.</ce:indexed-name><ce:surname>Bhatt</ce:surname></author></ref-authors><ref-sourcetitle>Neurosci Bull</ref-sourcetitle><ref-publicationyear first="2017"/><ref-volisspag><voliss volume="33"/><pagerange first="585" last="597"/></ref-volisspag><ref-text>1:CAS:528:DC%2BC2sXhsFOiur7N 28936761 5636742</ref-text></ref-info><ref-fulltext>Lotankar S, Prabhavalkar KS, Bhatt LK. Biomarkers for Parkinson's disease: recent advancement. Neurosci Bull. 2017;33:585-97.</ref-fulltext></reference><reference id="20"><ref-info><ref-title><ref-titletext>Oxidative stress and Parkinson's disease</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84937910217</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>J.</ce:initials><ce:indexed-name>Blesa J.</ce:indexed-name><ce:surname>Blesa</ce:surname></author><author seq="2"><ce:initials>I.</ce:initials><ce:indexed-name>Trigo-Damas I.</ce:indexed-name><ce:surname>Trigo-Damas</ce:surname></author><author seq="3"><ce:initials>A.</ce:initials><ce:indexed-name>Quiroga-Varela A.</ce:indexed-name><ce:surname>Quiroga-Varela</ce:surname></author><author seq="4"><ce:initials>V.R.</ce:initials><ce:indexed-name>Jackson-Lewis V.R.</ce:indexed-name><ce:surname>Jackson-Lewis</ce:surname></author></ref-authors><ref-sourcetitle>Front Neuroanat</ref-sourcetitle><ref-publicationyear first="2015"/><ref-volisspag><voliss volume="9"/><pagerange first="1" last="9"/></ref-volisspag></ref-info><ref-fulltext>Blesa J, Trigo-Damas I, Quiroga-Varela A, Jackson-Lewis VR. Oxidative stress and Parkinson's disease. Front Neuroanat. 2015;9:1-9.</ref-fulltext></reference><reference id="21"><ref-info><ref-title><ref-titletext>Neuromelanin of the human substantia nigra: An update</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84891859053</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>F.A.</ce:initials><ce:indexed-name>Zucca F.A.</ce:indexed-name><ce:surname>Zucca</ce:surname></author><author seq="2"><ce:initials>E.</ce:initials><ce:indexed-name>Basso E.</ce:indexed-name><ce:surname>Basso</ce:surname></author><author seq="3"><ce:initials>F.A.</ce:initials><ce:indexed-name>Cupaioli F.A.</ce:indexed-name><ce:surname>Cupaioli</ce:surname></author><author seq="4"><ce:initials>E.</ce:initials><ce:indexed-name>Ferrari E.</ce:indexed-name><ce:surname>Ferrari</ce:surname></author><author seq="5"><ce:initials>D.</ce:initials><ce:indexed-name>Sulzer D.</ce:indexed-name><ce:surname>Sulzer</ce:surname></author><author seq="6"><ce:initials>L.</ce:initials><ce:indexed-name>Casella L.</ce:indexed-name><ce:surname>Casella</ce:surname></author><author seq="7"><ce:initials>L.</ce:initials><ce:indexed-name>Zecca L.</ce:indexed-name><ce:surname>Zecca</ce:surname></author></ref-authors><ref-sourcetitle>Neurotox Res</ref-sourcetitle><ref-publicationyear first="2014"/><ref-volisspag><voliss volume="25"/><pagerange first="13" last="23"/></ref-volisspag><ref-text>1:CAS:528:DC%2BC2cXkvFGksA%3D%3D 24155156</ref-text></ref-info><ref-fulltext>Zucca FA, Basso E, Cupaioli FA, Ferrari E, Sulzer D, Casella L, Zecca L. Neuromelanin of the human substantia nigra: an update. Neurotox Res. 2014;25:13-23.</ref-fulltext></reference><reference id="22"><ref-info><ref-title><ref-titletext>Role of oxidative stress in Parkinson's disease</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84883180845</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>O.</ce:initials><ce:indexed-name>Hwang O.</ce:indexed-name><ce:surname>Hwang</ce:surname></author></ref-authors><ref-sourcetitle>Exp Neurobiol</ref-sourcetitle><ref-publicationyear first="2013"/><ref-volisspag><voliss volume="22"/><pagerange first="11" last="17"/></ref-volisspag><ref-text>23585717 3620453</ref-text></ref-info><ref-fulltext>Hwang O. Role of oxidative stress in Parkinson's disease. Exp Neurobiol. 2013;22:11-7.</ref-fulltext></reference><reference id="23"><ref-info><ref-title><ref-titletext>Updates on immunity and inflammation in Parkinson disease pathology</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">85032218270</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>N.</ce:initials><ce:indexed-name>Joshi N.</ce:indexed-name><ce:surname>Joshi</ce:surname></author><author seq="2"><ce:initials>S.</ce:initials><ce:indexed-name>Singh S.</ce:indexed-name><ce:surname>Singh</ce:surname></author></ref-authors><ref-sourcetitle>J Neurosci Res</ref-sourcetitle><ref-publicationyear first="2018"/><ref-volisspag><voliss volume="96"/><pagerange first="379" last="390"/></ref-volisspag><ref-text>1:CAS:528:DC%2BC2sXhslWrtr3L 29072332</ref-text></ref-info><ref-fulltext>Joshi N, Singh S. Updates on immunity and inflammation in Parkinson disease pathology. J Neurosci Res. 2018;96:379-90.</ref-fulltext></reference><reference id="24"><ref-info><ref-title><ref-titletext>Association of a neuronal nitric oxide synthase gene polymorphism with levodopa-induced dyskinesia in Parkinson's disease</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">85051165993</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>B.L.</ce:initials><ce:indexed-name>Santos-Lobato B.L.</ce:indexed-name><ce:surname>Santos-Lobato</ce:surname></author><author seq="2"><ce:initials>V.</ce:initials><ce:indexed-name>Borges V.</ce:indexed-name><ce:surname>Borges</ce:surname></author><author seq="3"><ce:initials>H.B.</ce:initials><ce:indexed-name>Ferraz H.B.</ce:indexed-name><ce:surname>Ferraz</ce:surname></author><author seq="4"><ce:initials>I.F.</ce:initials><ce:indexed-name>Mata I.F.</ce:indexed-name><ce:surname>Mata</ce:surname></author><author seq="5"><ce:initials>C.P.</ce:initials><ce:indexed-name>Zabetian C.P.</ce:indexed-name><ce:surname>Zabetian</ce:surname></author><author seq="6"><ce:initials>V.</ce:initials><ce:indexed-name>Tumas V.</ce:indexed-name><ce:surname>Tumas</ce:surname></author></ref-authors><ref-sourcetitle>Nitric Oxide</ref-sourcetitle><ref-publicationyear first="2017"/><ref-volisspag><voliss volume="8"/><pagerange first="30002"/></ref-volisspag></ref-info><ref-fulltext>Santos-Lobato BL, Borges V, Ferraz HB, Mata IF, Zabetian CP, Tumas V. Association of a neuronal nitric oxide synthase gene polymorphism with levodopa-induced dyskinesia in Parkinson's disease. Nitric Oxide. 2017;8:30002.</ref-fulltext></reference><reference id="25"><ref-info><ref-title><ref-titletext>The role of biomarkers and imaging in Parkinson's disease</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84958121479</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>M.A.</ce:initials><ce:indexed-name>Algarni M.A.</ce:indexed-name><ce:surname>Algarni</ce:surname></author><author seq="2"><ce:initials>A.J.</ce:initials><ce:indexed-name>Stoessl A.J.</ce:indexed-name><ce:surname>Stoessl</ce:surname></author></ref-authors><ref-sourcetitle>Expert Rev Neurother</ref-sourcetitle><ref-publicationyear first="2016"/><ref-volisspag><voliss volume="16"/><pagerange first="187" last="203"/></ref-volisspag><ref-text>1:CAS:528:DC%2BC28XhvFOrurs%3D 26829357</ref-text></ref-info><ref-fulltext>Algarni MA, Stoessl AJ. The role of biomarkers and imaging in Parkinson's disease. Expert Rev Neurother. 2016;16:187-203.</ref-fulltext></reference><reference id="26"><ref-info><ref-title><ref-titletext>Oxidative stress and antioxidant defense</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84857274709</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>E.</ce:initials><ce:indexed-name>Birben E.</ce:indexed-name><ce:surname>Birben</ce:surname></author><author seq="2"><ce:initials>U.M.</ce:initials><ce:indexed-name>Sahiner U.M.</ce:indexed-name><ce:surname>Sahiner</ce:surname></author><author seq="3"><ce:initials>C.</ce:initials><ce:indexed-name>Sackesen C.</ce:indexed-name><ce:surname>Sackesen</ce:surname></author><author seq="4"><ce:initials>S.</ce:initials><ce:indexed-name>Erzurum S.</ce:indexed-name><ce:surname>Erzurum</ce:surname></author><author seq="5"><ce:initials>O.</ce:initials><ce:indexed-name>Kalayci O.</ce:indexed-name><ce:surname>Kalayci</ce:surname></author></ref-authors><ref-sourcetitle>World Allergy Organ J</ref-sourcetitle><ref-publicationyear first="2012"/><ref-volisspag><voliss volume="5"/><pagerange first="9" last="19"/></ref-volisspag><ref-text>1:CAS:528:DC%2BC38XltFOqsLs%3D 3488923 3488923</ref-text></ref-info><ref-fulltext>Birben E, Sahiner UM, Sackesen C, Erzurum S, Kalayci O. Oxidative stress and antioxidant defense. World Allergy Organ J. 2012;5:9-19.</ref-fulltext></reference><reference id="27"><ref-info><ref-title><ref-titletext>Targeting urate to reduce oxidative stress in Parkinson disease</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">85021191697</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>G.F.</ce:initials><ce:indexed-name>Crotty G.F.</ce:indexed-name><ce:surname>Crotty</ce:surname></author><author seq="2"><ce:initials>A.</ce:initials><ce:indexed-name>Ascherio A.</ce:indexed-name><ce:surname>Ascherio</ce:surname></author><author seq="3"><ce:initials>M.A.</ce:initials><ce:indexed-name>Schwarzschild M.A.</ce:indexed-name><ce:surname>Schwarzschild</ce:surname></author></ref-authors><ref-sourcetitle>Exp Neurol</ref-sourcetitle><ref-publicationyear first="2017"/><ref-volisspag><voliss volume="298"/><pagerange first="210" last="224"/></ref-volisspag><ref-text>1:CAS:528:DC%2BC2sXhtVGms7vK 28622913 5693633</ref-text></ref-info><ref-fulltext>Crotty GF, Ascherio A, Schwarzschild MA. Targeting urate to reduce oxidative stress in Parkinson disease. Exp Neurol. 2017;298:210-24.</ref-fulltext></reference><reference id="28"><ref-info><ref-title><ref-titletext>Brain imaging for oxidative stress and mitochondrial dysfunction in neurodegenerative diseases</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84929908626</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>H.</ce:initials><ce:indexed-name>Okazawa H.</ce:indexed-name><ce:surname>Okazawa</ce:surname></author><author seq="2"><ce:initials>M.</ce:initials><ce:indexed-name>Ikawa M.</ce:indexed-name><ce:surname>Ikawa</ce:surname></author><author seq="3"><ce:initials>T.</ce:initials><ce:indexed-name>Tsujikawa T.</ce:indexed-name><ce:surname>Tsujikawa</ce:surname></author><author seq="4"><ce:initials>Y.</ce:initials><ce:indexed-name>Kiyono Y.</ce:indexed-name><ce:surname>Kiyono</ce:surname></author><author seq="5"><ce:initials>M.</ce:initials><ce:indexed-name>Yoneda M.</ce:indexed-name><ce:surname>Yoneda</ce:surname></author></ref-authors><ref-sourcetitle>Q J Nucl Med Mol Imaging</ref-sourcetitle><ref-publicationyear first="2014"/><ref-volisspag><voliss volume="58"/><pagerange first="387" last="397"/></ref-volisspag><ref-text>1:STN:280:DC%2BC2M3ltlSmsA%3D%3D 25366710</ref-text></ref-info><ref-fulltext>Okazawa H, Ikawa M, Tsujikawa T, Kiyono Y, Yoneda M. Brain imaging for oxidative stress and mitochondrial dysfunction in neurodegenerative diseases. Q J Nucl Med Mol Imaging. 2014;58:387-97.</ref-fulltext></reference><reference id="29"><ref-info><ref-title><ref-titletext>Mitochondrial impairment in microglia amplifies NLRP3 inflammasome proinflammatory signaling in cell culture and animal models of Parkinson's disease</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">85042799222</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>S.</ce:initials><ce:indexed-name>Sarkar S.</ce:indexed-name><ce:surname>Sarkar</ce:surname></author><author seq="2"><ce:initials>E.</ce:initials><ce:indexed-name>Malovic E.</ce:indexed-name><ce:surname>Malovic</ce:surname></author><author seq="3"><ce:initials>D.S.</ce:initials><ce:indexed-name>Harishchandra D.S.</ce:indexed-name><ce:surname>Harishchandra</ce:surname></author><author seq="4"><ce:initials>S.</ce:initials><ce:indexed-name>Ghaisas S.</ce:indexed-name><ce:surname>Ghaisas</ce:surname></author><author seq="5"><ce:initials>N.</ce:initials><ce:indexed-name>Panicker N.</ce:indexed-name><ce:surname>Panicker</ce:surname></author><author seq="6"><ce:initials>A.</ce:initials><ce:indexed-name>Charli A.</ce:indexed-name><ce:surname>Charli</ce:surname></author><author seq="7"><ce:initials>B.N.</ce:initials><ce:indexed-name>Palanisamy B.N.</ce:indexed-name><ce:surname>Palanisamy</ce:surname></author><author seq="8"><ce:initials>D.</ce:initials><ce:indexed-name>Rokad D.</ce:indexed-name><ce:surname>Rokad</ce:surname></author><author seq="9"><ce:initials>H.</ce:initials><ce:indexed-name>Jin H.</ce:indexed-name><ce:surname>Jin</ce:surname></author><author seq="10"><ce:initials>V.</ce:initials><ce:indexed-name>Anantharam V.</ce:indexed-name><ce:surname>Anantharam</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>NPJ Parkinsons Dis</ref-sourcetitle><ref-publicationyear first="2017"/><ref-volisspag><voliss volume="3"/><pagerange first="17" last="0032"/></ref-volisspag></ref-info><ref-fulltext>Sarkar S, Malovic E, Harishchandra DS, Ghaisas S, Panicker N, Charli A, Palanisamy BN, Rokad D, Jin H, Anantharam V, et al. Mitochondrial impairment in microglia amplifies NLRP3 inflammasome proinflammatory signaling in cell culture and animal models of Parkinson's disease. NPJ Parkinsons Dis. 2017;3:017-0032.</ref-fulltext></reference><reference id="30"><ref-info><ref-title><ref-titletext>The NLRP3 inflammasome is involved in the pathogenesis of Parkinson's disease in rats</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">85014032657</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>Z.</ce:initials><ce:indexed-name>Mao Z.</ce:indexed-name><ce:surname>Mao</ce:surname></author><author seq="2"><ce:initials>C.</ce:initials><ce:indexed-name>Liu C.</ce:indexed-name><ce:surname>Liu</ce:surname></author><author seq="3"><ce:initials>S.</ce:initials><ce:indexed-name>Ji S.</ce:indexed-name><ce:surname>Ji</ce:surname></author><author seq="4"><ce:initials>Q.</ce:initials><ce:indexed-name>Yang Q.</ce:indexed-name><ce:surname>Yang</ce:surname></author><author seq="5"><ce:initials>H.</ce:initials><ce:indexed-name>Ye H.</ce:indexed-name><ce:surname>Ye</ce:surname></author><author seq="6"><ce:initials>H.</ce:initials><ce:indexed-name>Han H.</ce:indexed-name><ce:surname>Han</ce:surname></author><author seq="7"><ce:initials>Z.</ce:initials><ce:indexed-name>Xue Z.</ce:indexed-name><ce:surname>Xue</ce:surname></author></ref-authors><ref-sourcetitle>Neurochem Res</ref-sourcetitle><ref-publicationyear first="2017"/><ref-volisspag><voliss volume="42"/><pagerange first="1104" last="1115"/></ref-volisspag><ref-text>1:CAS:528:DC%2BC2sXjs1Glu78%3D 28247334</ref-text></ref-info><ref-fulltext>Mao Z, Liu C, Ji S, Yang Q, Ye H, Han H, Xue Z. The NLRP3 inflammasome is involved in the pathogenesis of Parkinson's disease in rats. Neurochem Res. 2017;42:1104-15.</ref-fulltext></reference><reference id="31"><ref-info><ref-title><ref-titletext>Inflammatory cytokine gene polymorphisms and increased risk of Parkinson disease</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">34250312421</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>A.D.</ce:initials><ce:indexed-name>Wahner A.D.</ce:indexed-name><ce:surname>Wahner</ce:surname></author><author seq="2"><ce:initials>J.S.</ce:initials><ce:indexed-name>Sinsheimer J.S.</ce:indexed-name><ce:surname>Sinsheimer</ce:surname></author><author seq="3"><ce:initials>J.M.</ce:initials><ce:indexed-name>Bronstein J.M.</ce:indexed-name><ce:surname>Bronstein</ce:surname></author><author seq="4"><ce:initials>B.</ce:initials><ce:indexed-name>Ritz B.</ce:indexed-name><ce:surname>Ritz</ce:surname></author></ref-authors><ref-sourcetitle>Arch Neurol</ref-sourcetitle><ref-publicationyear first="2007"/><ref-volisspag><voliss volume="64"/><pagerange first="836" last="840"/></ref-volisspag><ref-text>17562931</ref-text></ref-info><ref-fulltext>Wahner AD, Sinsheimer JS, Bronstein JM, Ritz B. Inflammatory cytokine gene polymorphisms and increased risk of Parkinson disease. Arch Neurol. 2007;64:836-40.</ref-fulltext></reference><reference id="32"><ref-info><ref-title><ref-titletext>Gene-environment interactions linking air pollution and inflammation in Parkinson's disease</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84988014743</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>P.C.</ce:initials><ce:indexed-name>Lee P.C.</ce:indexed-name><ce:surname>Lee</ce:surname></author><author seq="2"><ce:initials>O.</ce:initials><ce:indexed-name>Raaschou-Nielsen O.</ce:indexed-name><ce:surname>Raaschou-Nielsen</ce:surname></author><author seq="3"><ce:initials>C.M.</ce:initials><ce:indexed-name>Lill C.M.</ce:indexed-name><ce:surname>Lill</ce:surname></author><author seq="4"><ce:initials>L.</ce:initials><ce:indexed-name>Bertram L.</ce:indexed-name><ce:surname>Bertram</ce:surname></author><author seq="5"><ce:initials>J.S.</ce:initials><ce:indexed-name>Sinsheimer J.S.</ce:indexed-name><ce:surname>Sinsheimer</ce:surname></author><author seq="6"><ce:initials>J.</ce:initials><ce:indexed-name>Hansen J.</ce:indexed-name><ce:surname>Hansen</ce:surname></author><author seq="7"><ce:initials>B.</ce:initials><ce:indexed-name>Ritz B.</ce:indexed-name><ce:surname>Ritz</ce:surname></author></ref-authors><ref-sourcetitle>Environ Res</ref-sourcetitle><ref-publicationyear first="2016"/><ref-volisspag><voliss volume="151"/><pagerange first="713" last="720"/></ref-volisspag><ref-text>1:CAS:528:DC%2BC28XhsFajs7bJ 27640071</ref-text></ref-info><ref-fulltext>Lee PC, Raaschou-Nielsen O, Lill CM, Bertram L, Sinsheimer JS, Hansen J, Ritz B. Gene-environment interactions linking air pollution and inflammation in Parkinson's disease. Environ Res. 2016;151:713-20.</ref-fulltext></reference><reference id="33"><ref-info><ref-title><ref-titletext>TNF-alpha -308 G/A and -238 G/A promoter polymorphisms and sporadic Parkinson's disease in an Italian cohort</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">85037699176</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>C.</ce:initials><ce:indexed-name>Agliardi C.</ce:indexed-name><ce:surname>Agliardi</ce:surname></author><author seq="2"><ce:initials>F.R.</ce:initials><ce:indexed-name>Guerini F.R.</ce:indexed-name><ce:surname>Guerini</ce:surname></author><author seq="3"><ce:initials>M.</ce:initials><ce:indexed-name>Zanzottera M.</ce:indexed-name><ce:surname>Zanzottera</ce:surname></author><author seq="4"><ce:initials>G.</ce:initials><ce:indexed-name>Riboldazzi G.</ce:indexed-name><ce:surname>Riboldazzi</ce:surname></author><author seq="5"><ce:initials>R.</ce:initials><ce:indexed-name>Zangaglia R.</ce:indexed-name><ce:surname>Zangaglia</ce:surname></author><author seq="6"><ce:initials>G.</ce:initials><ce:indexed-name>Bono G.</ce:indexed-name><ce:surname>Bono</ce:surname></author><author seq="7"><ce:initials>C.</ce:initials><ce:indexed-name>Casali C.</ce:indexed-name><ce:surname>Casali</ce:surname></author><author seq="8"><ce:initials>C.</ce:initials><ce:indexed-name>Di Lorenzo C.</ce:indexed-name><ce:surname>Di Lorenzo</ce:surname></author><author seq="9"><ce:initials>C.</ce:initials><ce:indexed-name>Pacchetti C.</ce:indexed-name><ce:surname>Pacchetti</ce:surname></author><author seq="10"><ce:initials>R.</ce:initials><ce:indexed-name>Nemni R.</ce:indexed-name><ce:surname>Nemni</ce:surname></author><author seq="11"><ce:initials>M.</ce:initials><ce:indexed-name>Clerici M.</ce:indexed-name><ce:surname>Clerici</ce:surname></author></ref-authors><ref-sourcetitle>J Neurol Sci</ref-sourcetitle><ref-publicationyear first="2018"/><ref-volisspag><voliss volume="385"/><pagerange first="45" last="48"/></ref-volisspag><ref-text>1:CAS:528:DC%2BC2sXhvFOhsbjK 29406912</ref-text></ref-info><ref-fulltext>Agliardi C, Guerini FR, Zanzottera M, Riboldazzi G, Zangaglia R, Bono G, Casali C, Di Lorenzo C, Pacchetti C, Nemni R, Clerici M. TNF-alpha -308 G/A and -238 G/A promoter polymorphisms and sporadic Parkinson's disease in an Italian cohort. J Neurol Sci. 2018;385:45-8.</ref-fulltext></reference><reference id="34"><ref-info><ref-title><ref-titletext>Association of NQO1 and TNF polymorphisms with Parkinson's disease: A meta-analysis of 15 genetic association studies</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84923138873</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>D.</ce:initials><ce:indexed-name>Dai D.</ce:indexed-name><ce:surname>Dai</ce:surname></author><author seq="2"><ce:initials>P.</ce:initials><ce:indexed-name>Lin P.</ce:indexed-name><ce:surname>Lin</ce:surname></author><author seq="3"><ce:initials>Y.</ce:initials><ce:indexed-name>Wang Y.</ce:indexed-name><ce:surname>Wang</ce:surname></author><author seq="4"><ce:initials>X.</ce:initials><ce:indexed-name>Zhou X.</ce:indexed-name><ce:surname>Zhou</ce:surname></author><author seq="5"><ce:initials>J.</ce:initials><ce:indexed-name>Tao J.</ce:indexed-name><ce:surname>Tao</ce:surname></author><author seq="6"><ce:initials>D.</ce:initials><ce:indexed-name>Jiang D.</ce:indexed-name><ce:surname>Jiang</ce:surname></author><author seq="7"><ce:initials>H.</ce:initials><ce:indexed-name>Zhou H.</ce:indexed-name><ce:surname>Zhou</ce:surname></author><author seq="8"><ce:initials>P.</ce:initials><ce:indexed-name>Ru P.</ce:indexed-name><ce:surname>Ru</ce:surname></author><author seq="9"><ce:initials>G.</ce:initials><ce:indexed-name>Pan G.</ce:indexed-name><ce:surname>Pan</ce:surname></author><author seq="10"><ce:initials>J.</ce:initials><ce:indexed-name>Li J.</ce:indexed-name><ce:surname>Li</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Biomed Rep</ref-sourcetitle><ref-publicationyear first="2014"/><ref-volisspag><voliss volume="2"/><pagerange first="713" last="718"/></ref-volisspag><ref-text>1:CAS:528:DC%2BC2cXhs1Ogsb7O 25054016 4106539</ref-text></ref-info><ref-fulltext>Dai D, Lin P, Wang Y, Zhou X, Tao J, Jiang D, Zhou H, Ru P, Pan G, Li J, et al. Association of NQO1 and TNF polymorphisms with Parkinson's disease: a meta-analysis of 15 genetic association studies. Biomed Rep. 2014;2:713-8.</ref-fulltext></reference><reference id="35"><ref-info><ref-title><ref-titletext>Tumor necrosis factor-alpha promoter polymorphism is associated with the risk of Parkinson's disease</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">34247323856</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>Y.R.</ce:initials><ce:indexed-name>Wu Y.R.</ce:indexed-name><ce:surname>Wu</ce:surname></author><author seq="2"><ce:initials>I.H.</ce:initials><ce:indexed-name>Feng I.H.</ce:indexed-name><ce:surname>Feng</ce:surname></author><author seq="3"><ce:initials>R.K.</ce:initials><ce:indexed-name>Lyu R.K.</ce:indexed-name><ce:surname>Lyu</ce:surname></author><author seq="4"><ce:initials>K.H.</ce:initials><ce:indexed-name>Chang K.H.</ce:indexed-name><ce:surname>Chang</ce:surname></author><author seq="5"><ce:initials>Y.Y.</ce:initials><ce:indexed-name>Lin Y.Y.</ce:indexed-name><ce:surname>Lin</ce:surname></author><author seq="6"><ce:initials>H.</ce:initials><ce:indexed-name>Chan H.</ce:indexed-name><ce:surname>Chan</ce:surname></author><author seq="7"><ce:initials>F.J.</ce:initials><ce:indexed-name>Hu F.J.</ce:indexed-name><ce:surname>Hu</ce:surname></author><author seq="8"><ce:initials>G.J.</ce:initials><ce:indexed-name>Lee-Chen G.J.</ce:indexed-name><ce:surname>Lee-Chen</ce:surname></author><author seq="9"><ce:initials>C.M.</ce:initials><ce:indexed-name>Chen C.M.</ce:indexed-name><ce:surname>Chen</ce:surname></author></ref-authors><ref-sourcetitle>Am J Med Genet B Neuropsychiatr Genet</ref-sourcetitle><ref-publicationyear first="2007"/><ref-volisspag><voliss volume="5"/><pagerange first="300" last="304"/></ref-volisspag></ref-info><ref-fulltext>Wu YR, Feng IH, Lyu RK, Chang KH, Lin YY, Chan H, Hu FJ, Lee-Chen GJ, Chen CM. Tumor necrosis factor-alpha promoter polymorphism is associated with the risk of Parkinson's disease. Am J Med Genet B Neuropsychiatr Genet. 2007;5:300-4.</ref-fulltext></reference><reference id="36"><ref-info><ref-title><ref-titletext>Gender differences in the IL6 -174G&gt;C and ESR2 1730G&gt;A polymorphisms and the risk of Parkinson's disease</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84655169613</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>M.</ce:initials><ce:indexed-name>San Luciano M.</ce:indexed-name><ce:surname>San Luciano</ce:surname></author><author seq="2"><ce:initials>L.</ce:initials><ce:indexed-name>Ozelius L.</ce:indexed-name><ce:surname>Ozelius</ce:surname></author><author seq="3"><ce:initials>R.B.</ce:initials><ce:indexed-name>Lipton R.B.</ce:indexed-name><ce:surname>Lipton</ce:surname></author><author seq="4"><ce:initials>D.</ce:initials><ce:indexed-name>Raymond D.</ce:indexed-name><ce:surname>Raymond</ce:surname></author><author seq="5"><ce:initials>S.B.</ce:initials><ce:indexed-name>Bressman S.B.</ce:indexed-name><ce:surname>Bressman</ce:surname></author><author seq="6"><ce:initials>R.</ce:initials><ce:indexed-name>Saunders-Pullman R.</ce:indexed-name><ce:surname>Saunders-Pullman</ce:surname></author></ref-authors><ref-sourcetitle>Neurosci Lett</ref-sourcetitle><ref-publicationyear first="2012"/><ref-volisspag><voliss volume="506"/><pagerange first="312" last="316"/></ref-volisspag><ref-text>1:CAS:528:DC%2BC38Xhtlyjug%3D%3D 22155094</ref-text></ref-info><ref-fulltext>San Luciano M, Ozelius L, Lipton RB, Raymond D, Bressman SB, Saunders-Pullman R. Gender differences in the IL6 -174G&gt;C and ESR2 1730G&gt;A polymorphisms and the risk of Parkinson's disease. Neurosci Lett. 2012;506:312-6.</ref-fulltext></reference><reference id="37"><ref-info><ref-title><ref-titletext>Nitric oxide synthase genes and their interactions with environmental factors in Parkinson's disease</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">52649158749</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>D.B.</ce:initials><ce:indexed-name>Hancock D.B.</ce:indexed-name><ce:surname>Hancock</ce:surname></author><author seq="2"><ce:initials>E.R.</ce:initials><ce:indexed-name>Martin E.R.</ce:indexed-name><ce:surname>Martin</ce:surname></author><author seq="3"><ce:initials>J.M.</ce:initials><ce:indexed-name>Vance J.M.</ce:indexed-name><ce:surname>Vance</ce:surname></author><author seq="4"><ce:initials>W.K.</ce:initials><ce:indexed-name>Scott W.K.</ce:indexed-name><ce:surname>Scott</ce:surname></author></ref-authors><ref-sourcetitle>Neurogenetics</ref-sourcetitle><ref-publicationyear first="2008"/><ref-volisspag><voliss volume="9"/><pagerange first="249" last="262"/></ref-volisspag><ref-text>1:CAS:528:DC%2BD1cXhtFKhu73F 18663495 2630458</ref-text></ref-info><ref-fulltext>Hancock DB, Martin ER, Vance JM, Scott WK. Nitric oxide synthase genes and their interactions with environmental factors in Parkinson's disease. Neurogenetics. 2008;9:249-62.</ref-fulltext></reference><reference id="38"><ref-info><ref-title><ref-titletext>Glycoproteomics in neurodegenerative diseases</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">73849150680</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>H.</ce:initials><ce:indexed-name>Hwang H.</ce:indexed-name><ce:surname>Hwang</ce:surname></author><author seq="2"><ce:initials>J.</ce:initials><ce:indexed-name>Zhang J.</ce:indexed-name><ce:surname>Zhang</ce:surname></author><author seq="3"><ce:initials>K.A.</ce:initials><ce:indexed-name>Chung K.A.</ce:indexed-name><ce:surname>Chung</ce:surname></author><author seq="4"><ce:initials>J.B.</ce:initials><ce:indexed-name>Leverenz J.B.</ce:indexed-name><ce:surname>Leverenz</ce:surname></author><author seq="5"><ce:initials>C.P.</ce:initials><ce:indexed-name>Zabetian C.P.</ce:indexed-name><ce:surname>Zabetian</ce:surname></author><author seq="6"><ce:initials>E.R.</ce:initials><ce:indexed-name>Peskind E.R.</ce:indexed-name><ce:surname>Peskind</ce:surname></author><author seq="7"><ce:initials>J.</ce:initials><ce:indexed-name>Jankovic J.</ce:indexed-name><ce:surname>Jankovic</ce:surname></author><author seq="8"><ce:initials>Z.</ce:initials><ce:indexed-name>Su Z.</ce:indexed-name><ce:surname>Su</ce:surname></author><author seq="9"><ce:initials>A.M.</ce:initials><ce:indexed-name>Hancock A.M.</ce:indexed-name><ce:surname>Hancock</ce:surname></author><author seq="10"><ce:initials>C.</ce:initials><ce:indexed-name>Pan C.</ce:indexed-name><ce:surname>Pan</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Mass Spectrom Rev</ref-sourcetitle><ref-publicationyear first="2010"/><ref-volisspag><voliss volume="29"/><pagerange first="79" last="125"/></ref-volisspag><ref-text>1:CAS:528:DC%2BC3cXhs1Kls7o%3D 19358229 2799547</ref-text></ref-info><ref-fulltext>Hwang H, Zhang J, Chung KA, Leverenz JB, Zabetian CP, Peskind ER, Jankovic J, Su Z, Hancock AM, Pan C, et al. Glycoproteomics in neurodegenerative diseases. Mass Spectrom Rev. 2010;29:79-125.</ref-fulltext></reference><reference id="39"><ref-info><ref-title><ref-titletext>The effect of a promoter polymorphism on the transcription of nitric oxide synthase 1 and its relevance to Parkinson's disease</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">69249221597</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>T.</ce:initials><ce:indexed-name>Rife T.</ce:indexed-name><ce:surname>Rife</ce:surname></author><author seq="2"><ce:initials>B.</ce:initials><ce:indexed-name>Rasoul B.</ce:indexed-name><ce:surname>Rasoul</ce:surname></author><author seq="3"><ce:initials>N.</ce:initials><ce:indexed-name>Pullen N.</ce:indexed-name><ce:surname>Pullen</ce:surname></author><author seq="4"><ce:initials>D.</ce:initials><ce:indexed-name>Mitchell D.</ce:indexed-name><ce:surname>Mitchell</ce:surname></author><author seq="5"><ce:initials>K.</ce:initials><ce:indexed-name>Grathwol K.</ce:indexed-name><ce:surname>Grathwol</ce:surname></author><author seq="6"><ce:initials>J.</ce:initials><ce:indexed-name>Kurth J.</ce:indexed-name><ce:surname>Kurth</ce:surname></author></ref-authors><ref-sourcetitle>J Neurosci Res</ref-sourcetitle><ref-publicationyear first="2009"/><ref-volisspag><voliss volume="87"/><pagerange first="2319" last="2325"/></ref-volisspag><ref-text>1:CAS:528:DC%2BD1MXnt1SisLg%3D 19326438</ref-text></ref-info><ref-fulltext>Rife T, Rasoul B, Pullen N, Mitchell D, Grathwol K, Kurth J. The effect of a promoter polymorphism on the transcription of nitric oxide synthase 1 and its relevance to Parkinson's disease. J Neurosci Res. 2009;87:2319-25.</ref-fulltext></reference><reference id="40"><ref-info><ref-title><ref-titletext>Association of polymorphism of neuronal nitric oxide synthase gene with risk to Parkinson's disease</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84931088731</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>S.P.</ce:initials><ce:indexed-name>Gupta S.P.</ce:indexed-name><ce:surname>Gupta</ce:surname></author><author seq="2"><ce:initials>R.</ce:initials><ce:indexed-name>Kamal R.</ce:indexed-name><ce:surname>Kamal</ce:surname></author><author seq="3"><ce:initials>S.K.</ce:initials><ce:indexed-name>Mishra S.K.</ce:indexed-name><ce:surname>Mishra</ce:surname></author><author seq="4"><ce:initials>M.K.</ce:initials><ce:indexed-name>Singh M.K.</ce:indexed-name><ce:surname>Singh</ce:surname></author><author seq="5"><ce:initials>R.</ce:initials><ce:indexed-name>Shukla R.</ce:indexed-name><ce:surname>Shukla</ce:surname></author><author seq="6"><ce:initials>M.P.</ce:initials><ce:indexed-name>Singh M.P.</ce:indexed-name><ce:surname>Singh</ce:surname></author></ref-authors><ref-sourcetitle>Mol Neurobiol</ref-sourcetitle><ref-publicationyear first="2016"/><ref-volisspag><voliss volume="53"/><pagerange first="3309" last="3314"/></ref-volisspag><ref-text>1:CAS:528:DC%2BC2MXhtVaqsLnO 26081147</ref-text></ref-info><ref-fulltext>Gupta SP, Kamal R, Mishra SK, Singh MK, Shukla R, Singh MP. Association of polymorphism of neuronal nitric oxide synthase gene with risk to Parkinson's disease. Mol Neurobiol. 2016;53:3309-14.</ref-fulltext></reference><reference id="41"><ref-info><ref-title><ref-titletext>Cellular glutathione peroxidase in human brain: Cellular distribution, and its potential role in the degradation of Lewy bodies in Parkinson's disease and dementia with Lewy bodies</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">57049169723</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>J.H.</ce:initials><ce:indexed-name>Power J.H.</ce:indexed-name><ce:surname>Power</ce:surname></author><author seq="2"><ce:initials>P.C.</ce:initials><ce:indexed-name>Blumbergs P.C.</ce:indexed-name><ce:surname>Blumbergs</ce:surname></author></ref-authors><ref-sourcetitle>Acta Neuropathol</ref-sourcetitle><ref-publicationyear first="2009"/><ref-volisspag><voliss volume="117"/><pagerange first="63" last="73"/></ref-volisspag><ref-text>1:CAS:528:DC%2BD1cXhsVeksrfM 18853169</ref-text></ref-info><ref-fulltext>Power JH, Blumbergs PC. Cellular glutathione peroxidase in human brain: cellular distribution, and its potential role in the degradation of Lewy bodies in Parkinson's disease and dementia with Lewy bodies. Acta Neuropathol. 2009;117:63-73.</ref-fulltext></reference><reference id="42"><ref-info><ref-title><ref-titletext>Synergy between glutathione peroxidase-1 and astrocytic growth factors suppresses free radical generation and protects dopaminergic neurons against 6-hydroxydopamine</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">79957490305</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>M.</ce:initials><ce:indexed-name>Gardaneh M.</ce:indexed-name><ce:surname>Gardaneh</ce:surname></author><author seq="2"><ce:initials>M.</ce:initials><ce:indexed-name>Gholami M.</ce:indexed-name><ce:surname>Gholami</ce:surname></author><author seq="3"><ce:initials>N.</ce:initials><ce:indexed-name>Maghsoudi N.</ce:indexed-name><ce:surname>Maghsoudi</ce:surname></author></ref-authors><ref-sourcetitle>Rejuvenation Res</ref-sourcetitle><ref-publicationyear first="2011"/><ref-volisspag><voliss volume="14"/><pagerange first="195" last="204"/></ref-volisspag><ref-text>1:CAS:528:DC%2BC3MXmtlyrsL4%3D 21222532 3093024</ref-text></ref-info><ref-fulltext>Gardaneh M, Gholami M, Maghsoudi N. Synergy between glutathione peroxidase-1 and astrocytic growth factors suppresses free radical generation and protects dopaminergic neurons against 6-hydroxydopamine. Rejuvenation Res. 2011;14:195-204.</ref-fulltext></reference><reference id="43"><ref-info><ref-title><ref-titletext>Neurochemical and motor changes in mice with combined mutations linked to Parkinson's disease</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">85062358580</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>X.</ce:initials><ce:indexed-name>Bai X.</ce:indexed-name><ce:surname>Bai</ce:surname></author><author seq="2"><ce:initials>M.C.</ce:initials><ce:indexed-name>Wey M.C.</ce:indexed-name><ce:surname>Wey</ce:surname></author><author seq="3"><ce:initials>P.A.</ce:initials><ce:indexed-name>Martinez P.A.</ce:indexed-name><ce:surname>Martinez</ce:surname></author><author seq="4"><ce:initials>C.</ce:initials><ce:indexed-name>Shi C.</ce:indexed-name><ce:surname>Shi</ce:surname></author><author seq="5"><ce:initials>E.</ce:initials><ce:indexed-name>Fernandez E.</ce:indexed-name><ce:surname>Fernandez</ce:surname></author><author seq="6"><ce:initials>R.</ce:initials><ce:indexed-name>Strong R.</ce:indexed-name><ce:surname>Strong</ce:surname></author></ref-authors><ref-sourcetitle>Pathobiol Aging Age Relat Dis</ref-sourcetitle><ref-publicationyear first="2017"/><ref-volisspag><voliss volume="7"/><pagerange first="1" last="9"/></ref-volisspag></ref-info><ref-fulltext>Bai X, Wey MC, Martinez PA, Shi C, Fernandez E, Strong R. Neurochemical and motor changes in mice with combined mutations linked to Parkinson's disease. Pathobiol Aging Age Relat Dis. 2017;7:1-9.</ref-fulltext></reference><reference id="44"><ref-info><ref-title><ref-titletext>Highly specific changes in antioxidant levels and lipid peroxidation in Parkinson's disease and its progression: Disease and staging biomarkers and new drug targets</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84958211385</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>C.C.</ce:initials><ce:indexed-name>De Farias C.C.</ce:indexed-name><ce:surname>De Farias</ce:surname></author><author seq="2"><ce:initials>M.</ce:initials><ce:indexed-name>Maes M.</ce:indexed-name><ce:surname>Maes</ce:surname></author><author seq="3"><ce:initials>K.L.</ce:initials><ce:indexed-name>Bonifacio K.L.</ce:indexed-name><ce:surname>Bonifacio</ce:surname></author><author seq="4"><ce:initials>C.C.</ce:initials><ce:indexed-name>Bortolasci C.C.</ce:indexed-name><ce:surname>Bortolasci</ce:surname></author><author seq="5"><ce:initials>N.A.</ce:initials><ce:indexed-name>De Souza N.A.</ce:indexed-name><ce:surname>De Souza</ce:surname></author><author seq="6"><ce:initials>F.F.</ce:initials><ce:indexed-name>Brinholi F.F.</ce:indexed-name><ce:surname>Brinholi</ce:surname></author><author seq="7"><ce:initials>A.K.</ce:initials><ce:indexed-name>Matsumoto A.K.</ce:indexed-name><ce:surname>Matsumoto</ce:surname></author><author seq="8"><ce:initials>M.A.</ce:initials><ce:indexed-name>Do Nascimento M.A.</ce:indexed-name><ce:surname>Do Nascimento</ce:surname></author><author seq="9"><ce:initials>L.B.</ce:initials><ce:indexed-name>De Melo L.B.</ce:indexed-name><ce:surname>De Melo</ce:surname></author><author seq="10"><ce:initials>S.L.</ce:initials><ce:indexed-name>Nixdorf S.L.</ce:indexed-name><ce:surname>Nixdorf</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Neurosci Lett</ref-sourcetitle><ref-publicationyear first="2016"/><ref-volisspag><voliss volume="617"/><pagerange first="66" last="71"/></ref-volisspag><ref-text>26861200</ref-text></ref-info><ref-fulltext>de Farias CC, Maes M, Bonifacio KL, Bortolasci CC, de Souza NA, Brinholi FF, Matsumoto AK, do Nascimento MA, de Melo LB, Nixdorf SL, et al. Highly specific changes in antioxidant levels and lipid peroxidation in Parkinson's disease and its progression: disease and staging biomarkers and new drug targets. Neurosci Lett. 2016;617:66-71.</ref-fulltext></reference><reference id="45"><ref-info><ref-title><ref-titletext>No association of four candidate genetic variants in MnSOD and SYNIII with Parkinson's disease in two Chinese populations</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84896110387</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>W.J.</ce:initials><ce:indexed-name>Yu W.J.</ce:indexed-name><ce:surname>Yu</ce:surname></author><author seq="2"><ce:initials>N.N.</ce:initials><ce:indexed-name>Li N.N.</ce:indexed-name><ce:surname>Li</ce:surname></author><author seq="3"><ce:initials>E.K.</ce:initials><ce:indexed-name>Tan E.K.</ce:indexed-name><ce:surname>Tan</ce:surname></author><author seq="4"><ce:initials>L.</ce:initials><ce:indexed-name>Cheng L.</ce:indexed-name><ce:surname>Cheng</ce:surname></author><author seq="5"><ce:initials>J.H.</ce:initials><ce:indexed-name>Zhang J.H.</ce:indexed-name><ce:surname>Zhang</ce:surname></author><author seq="6"><ce:initials>X.Y.</ce:initials><ce:indexed-name>Mao X.Y.</ce:indexed-name><ce:surname>Mao</ce:surname></author><author seq="7"><ce:initials>X.L.</ce:initials><ce:indexed-name>Chang X.L.</ce:indexed-name><ce:surname>Chang</ce:surname></author><author seq="8"><ce:initials>D.M.</ce:initials><ce:indexed-name>Zhao D.M.</ce:indexed-name><ce:surname>Zhao</ce:surname></author><author seq="9"><ce:initials>Q.</ce:initials><ce:indexed-name>Liao Q.</ce:indexed-name><ce:surname>Liao</ce:surname></author><author seq="10"><ce:initials>R.</ce:initials><ce:indexed-name>Peng R.</ce:indexed-name><ce:surname>Peng</ce:surname></author></ref-authors><ref-sourcetitle>PLoS One</ref-sourcetitle><ref-publicationyear first="2014"/><ref-volisspag><voliss volume="9"/><pagerange first="1" last="3"/></ref-volisspag></ref-info><ref-fulltext>Yu WJ, Li NN, Tan EK, Cheng L, Zhang JH, Mao XY, Chang XL, Zhao DM, Liao Q, Peng R. No association of four candidate genetic variants in MnSOD and SYNIII with Parkinson's disease in two Chinese populations. PLoS One. 2014;9:1-3.</ref-fulltext></reference><reference id="46"><ref-info><ref-title><ref-titletext>Genetic polymorphisms of superoxide dismutase in Parkinson's disease</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">0035412902</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>F.M.</ce:initials><ce:indexed-name>Farin F.M.</ce:indexed-name><ce:surname>Farin</ce:surname></author><author seq="2"><ce:initials>Y.</ce:initials><ce:indexed-name>Hitosis Y.</ce:indexed-name><ce:surname>Hitosis</ce:surname></author><author seq="3"><ce:initials>S.E.</ce:initials><ce:indexed-name>Hallagan S.E.</ce:indexed-name><ce:surname>Hallagan</ce:surname></author><author seq="4"><ce:initials>J.</ce:initials><ce:indexed-name>Kushleika J.</ce:indexed-name><ce:surname>Kushleika</ce:surname></author><author seq="5"><ce:initials>J.S.</ce:initials><ce:indexed-name>Woods J.S.</ce:indexed-name><ce:surname>Woods</ce:surname></author><author seq="6"><ce:initials>P.S.</ce:initials><ce:indexed-name>Janssen P.S.</ce:indexed-name><ce:surname>Janssen</ce:surname></author><author seq="7"><ce:initials>T.</ce:initials><ce:indexed-name>Smith-Weller T.</ce:indexed-name><ce:surname>Smith-Weller</ce:surname></author><author seq="8"><ce:initials>G.M.</ce:initials><ce:indexed-name>Franklin G.M.</ce:indexed-name><ce:surname>Franklin</ce:surname></author><author seq="9"><ce:initials>P.D.</ce:initials><ce:indexed-name>Swanson P.D.</ce:indexed-name><ce:surname>Swanson</ce:surname></author><author seq="10"><ce:initials>H.</ce:initials><ce:indexed-name>Checkoway H.</ce:indexed-name><ce:surname>Checkoway</ce:surname></author></ref-authors><ref-sourcetitle>Mov Disord</ref-sourcetitle><ref-publicationyear first="2001"/><ref-volisspag><voliss volume="16"/><pagerange first="705" last="707"/></ref-volisspag><ref-text>1:STN:280:DC%2BD3Mvjtlyrsg%3D%3D 11481695</ref-text></ref-info><ref-fulltext>Farin FM, Hitosis Y, Hallagan SE, Kushleika J, Woods JS, Janssen PS, Smith-Weller T, Franklin GM, Swanson PD, Checkoway H. Genetic polymorphisms of superoxide dismutase in Parkinson's disease. Mov Disord. 2001;16:705-7.</ref-fulltext></reference><reference id="47"><ref-info><ref-title><ref-titletext>Pharmacological treatment of Parkinson disease: A review</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84898775157</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>B.S.</ce:initials><ce:indexed-name>Connolly B.S.</ce:indexed-name><ce:surname>Connolly</ce:surname></author><author seq="2"><ce:initials>A.E.</ce:initials><ce:indexed-name>Lang A.E.</ce:indexed-name><ce:surname>Lang</ce:surname></author></ref-authors><ref-sourcetitle>Jama</ref-sourcetitle><ref-publicationyear first="2014"/><ref-volisspag><voliss volume="311"/><pagerange first="1670" last="1683"/></ref-volisspag><ref-text>24756517</ref-text></ref-info><ref-fulltext>Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. Jama. 2014;311:1670-83.</ref-fulltext></reference><reference id="48"><ref-info><ref-title><ref-titletext>A review of adverse events linked to dopamine agonists in the treatment of Parkinson's disease</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84958172149</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>R.</ce:initials><ce:indexed-name>Ceravolo R.</ce:indexed-name><ce:surname>Ceravolo</ce:surname></author><author seq="2"><ce:initials>C.</ce:initials><ce:indexed-name>Rossi C.</ce:indexed-name><ce:surname>Rossi</ce:surname></author><author seq="3"><ce:initials>E.</ce:initials><ce:indexed-name>Del Prete E.</ce:indexed-name><ce:surname>Del Prete</ce:surname></author><author seq="4"><ce:initials>U.</ce:initials><ce:indexed-name>Bonuccelli U.</ce:indexed-name><ce:surname>Bonuccelli</ce:surname></author></ref-authors><ref-sourcetitle>Expert Opin Drug Saf</ref-sourcetitle><ref-publicationyear first="2016"/><ref-volisspag><voliss volume="15"/><pagerange first="181" last="198"/></ref-volisspag><ref-text>1:CAS:528:DC%2BC28XhsFKht7w%3D 26646536</ref-text></ref-info><ref-fulltext>Ceravolo R, Rossi C, Del Prete E, Bonuccelli U. A review of adverse events linked to dopamine agonists in the treatment of Parkinson's disease. Expert Opin Drug Saf. 2016;15:181-98.</ref-fulltext></reference><reference id="49"><ref-info><ref-title><ref-titletext>Molecular basis of dopamine replacement therapy and its side effects in Parkinson's disease</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">85062332605</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>H.</ce:initials><ce:indexed-name>You H.</ce:indexed-name><ce:surname>You</ce:surname></author><author seq="2"><ce:initials>L.L.</ce:initials><ce:indexed-name>Mariani L.L.</ce:indexed-name><ce:surname>Mariani</ce:surname></author><author seq="3"><ce:initials>G.</ce:initials><ce:indexed-name>Mangone G.</ce:indexed-name><ce:surname>Mangone</ce:surname></author><author seq="4"><ce:initials>D.</ce:initials><ce:indexed-name>Le Febvre De Nailly D.</ce:indexed-name><ce:surname>Le Febvre De Nailly</ce:surname></author><author seq="5"><ce:initials>F.</ce:initials><ce:indexed-name>Charbonnier-Beaupel F.</ce:indexed-name><ce:surname>Charbonnier-Beaupel</ce:surname></author><author seq="6"><ce:initials>J.C.</ce:initials><ce:indexed-name>Corvol J.C.</ce:indexed-name><ce:surname>Corvol</ce:surname></author></ref-authors><ref-sourcetitle>Cell Tissue Res</ref-sourcetitle><ref-publicationyear first="2018"/><ref-volisspag><voliss volume="7"/><pagerange first="18" last="2813"/></ref-volisspag></ref-info><ref-fulltext>You H, Mariani LL, Mangone G, Le Febvre de Nailly D, Charbonnier-Beaupel F, Corvol JC. Molecular basis of dopamine replacement therapy and its side effects in Parkinson's disease. Cell Tissue Res. 2018;7:018-2813.</ref-fulltext></reference><reference id="50"><ref-info><refd-itemidlist><itemid idtype="SGR">85062366691</itemid></refd-itemidlist><ref-website><ce:e-address type="email">http://www.movementdisorders.org/MDS-Files1/PDFs/MDS-UPDRS-Rating-Scales/NewUPDRS7308final.pdf</ce:e-address></ref-website><ref-text>MDS-UPDRS</ref-text></ref-info><ref-fulltext>MDS-UPDRS [ http://www.movementdisorders.org/MDS-Files1/PDFs/MDS-UPDRS-Rating-Scales/NewUPDRS7308final.pdf ].</ref-fulltext></reference><reference id="51"><ref-info><ref-title><ref-titletext>Inflammation is genetically implicated in Parkinson's disease</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84938221814</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>N.</ce:initials><ce:indexed-name>Dzamko N.</ce:indexed-name><ce:surname>Dzamko</ce:surname></author><author seq="2"><ce:initials>C.L.</ce:initials><ce:indexed-name>Geczy C.L.</ce:indexed-name><ce:surname>Geczy</ce:surname></author><author seq="3"><ce:initials>G.M.</ce:initials><ce:indexed-name>Halliday G.M.</ce:indexed-name><ce:surname>Halliday</ce:surname></author></ref-authors><ref-sourcetitle>Neuroscience</ref-sourcetitle><ref-publicationyear first="2015"/><ref-volisspag><voliss volume="302"/><pagerange first="89" last="102"/></ref-volisspag><ref-text>1:CAS:528:DC%2BC2cXhvVemsLzP 25450953</ref-text></ref-info><ref-fulltext>Dzamko N, Geczy CL, Halliday GM. Inflammation is genetically implicated in Parkinson's disease. Neuroscience. 2015;302:89-102.</ref-fulltext></reference><reference id="52"><ref-info><ref-title><ref-titletext>NALP3 inflammasome activation in protein misfolding diseases</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84934917454</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>F.</ce:initials><ce:indexed-name>Shi F.</ce:indexed-name><ce:surname>Shi</ce:surname></author><author seq="2"><ce:initials>M.</ce:initials><ce:indexed-name>Kouadir M.</ce:indexed-name><ce:surname>Kouadir</ce:surname></author><author seq="3"><ce:initials>Y.</ce:initials><ce:indexed-name>Yang Y.</ce:indexed-name><ce:surname>Yang</ce:surname></author></ref-authors><ref-sourcetitle>Life Sci</ref-sourcetitle><ref-publicationyear first="2015"/><ref-volisspag><voliss volume="135"/><pagerange first="9" last="14"/></ref-volisspag><ref-text>1:CAS:528:DC%2BC2MXpsV2ht74%3D 26037399</ref-text></ref-info><ref-fulltext>Shi F, Kouadir M, Yang Y. NALP3 inflammasome activation in protein misfolding diseases. Life Sci. 2015;135:9-14.</ref-fulltext></reference><reference id="53"><ref-info><ref-title><ref-titletext>SNPinfo: Integrating GWAS and candidate gene information into functional SNP selection for genetic association studies</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">67849101182</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>Z.</ce:initials><ce:indexed-name>Xu Z.</ce:indexed-name><ce:surname>Xu</ce:surname></author><author seq="2"><ce:initials>J.A.</ce:initials><ce:indexed-name>Taylor J.A.</ce:indexed-name><ce:surname>Taylor</ce:surname></author></ref-authors><ref-sourcetitle>Nucleic Acids Res</ref-sourcetitle><ref-publicationyear first="2009"/><ref-volisspag><voliss volume="37"/><pagerange first="5"/></ref-volisspag></ref-info><ref-fulltext>Xu Z, Taylor JA. SNPinfo: integrating GWAS and candidate gene information into functional SNP selection for genetic association studies. Nucleic Acids Res. 2009;37:5.</ref-fulltext></reference><reference id="54"><ref-info><ref-title><ref-titletext>Systematic review of levodopa dose equivalency reporting in Parkinson's disease</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">78349261173</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>C.L.</ce:initials><ce:indexed-name>Tomlinson C.L.</ce:indexed-name><ce:surname>Tomlinson</ce:surname></author><author seq="2"><ce:initials>R.</ce:initials><ce:indexed-name>Stowe R.</ce:indexed-name><ce:surname>Stowe</ce:surname></author><author seq="3"><ce:initials>S.</ce:initials><ce:indexed-name>Patel S.</ce:indexed-name><ce:surname>Patel</ce:surname></author><author seq="4"><ce:initials>C.</ce:initials><ce:indexed-name>Rick C.</ce:indexed-name><ce:surname>Rick</ce:surname></author><author seq="5"><ce:initials>R.</ce:initials><ce:indexed-name>Gray R.</ce:indexed-name><ce:surname>Gray</ce:surname></author><author seq="6"><ce:initials>C.E.</ce:initials><ce:indexed-name>Clarke C.E.</ce:indexed-name><ce:surname>Clarke</ce:surname></author></ref-authors><ref-sourcetitle>Mov Disord</ref-sourcetitle><ref-publicationyear first="2010"/><ref-volisspag><voliss volume="25"/><pagerange first="2649" last="2653"/></ref-volisspag><ref-text>21069833</ref-text></ref-info><ref-fulltext>Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord. 2010;25:2649-53.</ref-fulltext></reference><reference id="55"><ref-info><ref-title><ref-titletext>From genomics to omics landscapes of Parkinson's disease: Revealing the molecular mechanisms</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">85047138007</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>S.</ce:initials><ce:indexed-name>Redensek S.</ce:indexed-name><ce:surname>Redensek</ce:surname></author><author seq="2"><ce:initials>V.</ce:initials><ce:indexed-name>Dolzan V.</ce:indexed-name><ce:surname>Dolzan</ce:surname></author><author seq="3"><ce:initials>T.</ce:initials><ce:indexed-name>Kunej T.</ce:indexed-name><ce:surname>Kunej</ce:surname></author></ref-authors><ref-sourcetitle>Omics</ref-sourcetitle><ref-publicationyear first="2018"/><ref-volisspag><voliss volume="22"/><pagerange first="1" last="16"/></ref-volisspag><ref-text>1:CAS:528:DC%2BC1cXhsVartrw%3D 29356624 5784788</ref-text></ref-info><ref-fulltext>Redensek S, Dolzan V, Kunej T. From genomics to omics landscapes of Parkinson's disease: revealing the molecular mechanisms. Omics. 2018;22:1-16.</ref-fulltext></reference><reference id="56"><ref-info><ref-title><ref-titletext>Excessive daytime sleepiness in patients with Parkinson's disease</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">79951742216</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>B.</ce:initials><ce:indexed-name>Knie B.</ce:indexed-name><ce:surname>Knie</ce:surname></author><author seq="2"><ce:initials>M.T.</ce:initials><ce:indexed-name>Mitra M.T.</ce:indexed-name><ce:surname>Mitra</ce:surname></author><author seq="3"><ce:initials>K.</ce:initials><ce:indexed-name>Logishetty K.</ce:indexed-name><ce:surname>Logishetty</ce:surname></author><author seq="4"><ce:initials>K.R.</ce:initials><ce:indexed-name>Chaudhuri K.R.</ce:indexed-name><ce:surname>Chaudhuri</ce:surname></author></ref-authors><ref-sourcetitle>CNS Drugs</ref-sourcetitle><ref-publicationyear first="2011"/><ref-volisspag><voliss volume="25"/><pagerange first="203" last="212"/></ref-volisspag><ref-text>1:CAS:528:DC%2BC3MXlvFWnu74%3D 21323392</ref-text></ref-info><ref-fulltext>Knie B, Mitra MT, Logishetty K, Chaudhuri KR. Excessive daytime sleepiness in patients with Parkinson's disease. CNS Drugs. 2011;25:203-12.</ref-fulltext></reference><reference id="57"><ref-info><ref-title><ref-titletext>A reassessment of risks and benefits of dopamine agonists in Parkinson's disease</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">69949085340</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>A.</ce:initials><ce:indexed-name>Antonini A.</ce:indexed-name><ce:surname>Antonini</ce:surname></author><author seq="2"><ce:initials>E.</ce:initials><ce:indexed-name>Tolosa E.</ce:indexed-name><ce:surname>Tolosa</ce:surname></author><author seq="3"><ce:initials>Y.</ce:initials><ce:indexed-name>Mizuno Y.</ce:indexed-name><ce:surname>Mizuno</ce:surname></author><author seq="4"><ce:initials>M.</ce:initials><ce:indexed-name>Yamamoto M.</ce:indexed-name><ce:surname>Yamamoto</ce:surname></author><author seq="5"><ce:initials>W.H.</ce:initials><ce:indexed-name>Poewe W.H.</ce:indexed-name><ce:surname>Poewe</ce:surname></author></ref-authors><ref-sourcetitle>Lancet Neurol</ref-sourcetitle><ref-publicationyear first="2009"/><ref-volisspag><voliss volume="8"/><pagerange first="929" last="937"/></ref-volisspag><ref-text>1:CAS:528:DC%2BD1MXht1Kitr7I 19709931</ref-text></ref-info><ref-fulltext>Antonini A, Tolosa E, Mizuno Y, Yamamoto M, Poewe WH. A reassessment of risks and benefits of dopamine agonists in Parkinson's disease. Lancet Neurol. 2009;8:929-37.</ref-fulltext></reference><reference id="58"><ref-info><ref-title><ref-titletext>Sleep disorders in Parkinson's disease</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84901839162</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>W.</ce:initials><ce:indexed-name>Schrempf W.</ce:indexed-name><ce:surname>Schrempf</ce:surname></author><author seq="2"><ce:initials>M.D.</ce:initials><ce:indexed-name>Brandt M.D.</ce:indexed-name><ce:surname>Brandt</ce:surname></author><author seq="3"><ce:initials>A.</ce:initials><ce:indexed-name>Storch A.</ce:indexed-name><ce:surname>Storch</ce:surname></author><author seq="4"><ce:initials>H.</ce:initials><ce:indexed-name>Reichmann H.</ce:indexed-name><ce:surname>Reichmann</ce:surname></author></ref-authors><ref-sourcetitle>J Park Dis</ref-sourcetitle><ref-publicationyear first="2014"/><ref-volisspag><voliss volume="4"/><pagerange first="211" last="221"/></ref-volisspag></ref-info><ref-fulltext>Schrempf W, Brandt MD, Storch A, Reichmann H. Sleep disorders in Parkinson's disease. J Park Dis. 2014;4:211-21.</ref-fulltext></reference><reference id="59"><ref-info><ref-title><ref-titletext>Piribedil-induced sleep attacks in patients without Parkinson disease: A case series</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">79959284131</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>A.</ce:initials><ce:indexed-name>Gouraud A.</ce:indexed-name><ce:surname>Gouraud</ce:surname></author><author seq="2"><ce:initials>A.</ce:initials><ce:indexed-name>Millaret A.</ce:indexed-name><ce:surname>Millaret</ce:surname></author><author seq="3"><ce:initials>J.</ce:initials><ce:indexed-name>Descotes J.</ce:indexed-name><ce:surname>Descotes</ce:surname></author><author seq="4"><ce:initials>T.</ce:initials><ce:indexed-name>Vial T.</ce:indexed-name><ce:surname>Vial</ce:surname></author></ref-authors><ref-sourcetitle>Clin Neuropharmacol</ref-sourcetitle><ref-publicationyear first="2011"/><ref-volisspag><voliss volume="34"/><pagerange first="104" last="107"/></ref-volisspag><ref-text>1:CAS:528:DC%2BC3MXmt1ymsbk%3D 21586915</ref-text></ref-info><ref-fulltext>Gouraud A, Millaret A, Descotes J, Vial T. Piribedil-induced sleep attacks in patients without Parkinson disease: a case series. Clin Neuropharmacol. 2011;34:104-7.</ref-fulltext></reference><reference id="60"><ref-info><ref-title><ref-titletext>Dopamine-induced nonmotor symptoms of Parkinson's disease</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">79959245006</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>A.</ce:initials><ce:indexed-name>Park A.</ce:indexed-name><ce:surname>Park</ce:surname></author><author seq="2"><ce:initials>M.</ce:initials><ce:indexed-name>Stacy M.</ce:indexed-name><ce:surname>Stacy</ce:surname></author></ref-authors><ref-sourcetitle>Parkinsons Dis</ref-sourcetitle><ref-publicationyear first="2011"/><ref-volisspag><pagerange first="11"/></ref-volisspag></ref-info><ref-fulltext>Park A, Stacy M. Dopamine-induced nonmotor symptoms of Parkinson's disease. Parkinsons Dis. 2011;485063:11.</ref-fulltext></reference><reference id="61"><ref-info><ref-title><ref-titletext>Spontaneous sleep in mice with targeted disruptions of neuronal or inducible nitric oxide synthase genes</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">0037989874</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>L.</ce:initials><ce:indexed-name>Chen L.</ce:indexed-name><ce:surname>Chen</ce:surname></author><author seq="2"><ce:initials>J.A.</ce:initials><ce:indexed-name>Majde J.A.</ce:indexed-name><ce:surname>Majde</ce:surname></author><author seq="3"><ce:initials>J.M.</ce:initials><ce:indexed-name>Krueger J.M.</ce:indexed-name><ce:surname>Krueger</ce:surname></author></ref-authors><ref-sourcetitle>Brain Res</ref-sourcetitle><ref-publicationyear first="2003"/><ref-volisspag><voliss volume="973"/><pagerange first="214" last="222"/></ref-volisspag><ref-text>1:CAS:528:DC%2BD3sXjsVWlsbk%3D 12738065</ref-text></ref-info><ref-fulltext>Chen L, Majde JA, Krueger JM. Spontaneous sleep in mice with targeted disruptions of neuronal or inducible nitric oxide synthase genes. Brain Res. 2003;973:214-22.</ref-fulltext></reference><reference id="62"><ref-info><ref-title><ref-titletext>A role for cortical nNOS/NK1 neurons in coupling homeostatic sleep drive to EEG slow wave activity</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84890280212</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>S.R.</ce:initials><ce:indexed-name>Morairty S.R.</ce:indexed-name><ce:surname>Morairty</ce:surname></author><author seq="2"><ce:initials>L.</ce:initials><ce:indexed-name>Dittrich L.</ce:indexed-name><ce:surname>Dittrich</ce:surname></author><author seq="3"><ce:initials>R.K.</ce:initials><ce:indexed-name>Pasumarthi R.K.</ce:indexed-name><ce:surname>Pasumarthi</ce:surname></author><author seq="4"><ce:initials>D.</ce:initials><ce:indexed-name>Valladao D.</ce:indexed-name><ce:surname>Valladao</ce:surname></author><author seq="5"><ce:initials>J.E.</ce:initials><ce:indexed-name>Heiss J.E.</ce:indexed-name><ce:surname>Heiss</ce:surname></author><author seq="6"><ce:initials>D.</ce:initials><ce:indexed-name>Gerashchenko D.</ce:indexed-name><ce:surname>Gerashchenko</ce:surname></author><author seq="7"><ce:initials>T.S.</ce:initials><ce:indexed-name>Kilduff T.S.</ce:indexed-name><ce:surname>Kilduff</ce:surname></author></ref-authors><ref-sourcetitle>Proc Natl Acad Sci U S A</ref-sourcetitle><ref-publicationyear first="2013"/><ref-volisspag><voliss volume="110"/><pagerange first="20272" last="20277"/></ref-volisspag><ref-text>1:CAS:528:DC%2BC3sXhvFKmsLzJ 24191004 3864296</ref-text></ref-info><ref-fulltext>Morairty SR, Dittrich L, Pasumarthi RK, Valladao D, Heiss JE, Gerashchenko D, Kilduff TS. A role for cortical nNOS/NK1 neurons in coupling homeostatic sleep drive to EEG slow wave activity. Proc Natl Acad Sci U S A. 2013;110:20272-7.</ref-fulltext></reference><reference id="63"><ref-info><ref-title><ref-titletext>Clinical review and treatment of select adverse effects of dopamine receptor agonists in Parkinson's disease</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">77950669992</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>L.D.</ce:initials><ce:indexed-name>Wood L.D.</ce:indexed-name><ce:surname>Wood</ce:surname></author></ref-authors><ref-sourcetitle>Drugs Aging</ref-sourcetitle><ref-publicationyear first="2010"/><ref-volisspag><voliss volume="27"/><pagerange first="295" last="310"/></ref-volisspag><ref-text>1:CAS:528:DC%2BC3cXntFCksrk%3D 20359261</ref-text></ref-info><ref-fulltext>Wood LD. Clinical review and treatment of select adverse effects of dopamine receptor agonists in Parkinson's disease. Drugs Aging. 2010;27:295-310.</ref-fulltext></reference><reference id="64"><ref-info><ref-title><ref-titletext>Antioxidant polymorphisms do not influence the risk of epilepsy or its drug resistance after neonatal hypoxic-ischemic brain injury</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">85013057138</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>K.</ce:initials><ce:indexed-name>Esih K.</ce:indexed-name><ce:surname>Esih</ce:surname></author><author seq="2"><ce:initials>K.</ce:initials><ce:indexed-name>Goricar K.</ce:indexed-name><ce:surname>Goricar</ce:surname></author><author seq="3"><ce:initials>V.</ce:initials><ce:indexed-name>Dolzan V.</ce:indexed-name><ce:surname>Dolzan</ce:surname></author><author seq="4"><ce:initials>Z.</ce:initials><ce:indexed-name>Rener-Primec Z.</ce:indexed-name><ce:surname>Rener-Primec</ce:surname></author></ref-authors><ref-sourcetitle>Seizure</ref-sourcetitle><ref-publicationyear first="2017"/><ref-volisspag><voliss volume="46"/><pagerange first="38" last="42"/></ref-volisspag><ref-text>28222320</ref-text></ref-info><ref-fulltext>Esih K, Goricar K, Dolzan V, Rener-Primec Z. Antioxidant polymorphisms do not influence the risk of epilepsy or its drug resistance after neonatal hypoxic-ischemic brain injury. Seizure. 2017;46:38-42.</ref-fulltext></reference><reference id="65"><ref-info><ref-title><ref-titletext>Parkinson's disease from the gut</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">85062365966</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>R.A.</ce:initials><ce:indexed-name>Liddle R.A.</ce:indexed-name><ce:surname>Liddle</ce:surname></author></ref-authors><ref-sourcetitle>Brain Res</ref-sourcetitle><ref-publicationyear first="2018"/><ref-volisspag><voliss volume="31"/><pagerange first="30018"/></ref-volisspag></ref-info><ref-fulltext>Liddle RA. Parkinson's disease from the gut. Brain Res. 2018;31:30018-0.</ref-fulltext></reference><reference id="66"><ref-info><ref-title><ref-titletext>Enteric nervous system manifestations of neurodegenerative disease</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">85062366135</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>A.</ce:initials><ce:indexed-name>Chalazonitis A.</ce:indexed-name><ce:surname>Chalazonitis</ce:surname></author><author seq="2"><ce:initials>M.</ce:initials><ce:indexed-name>Rao M.</ce:indexed-name><ce:surname>Rao</ce:surname></author></ref-authors><ref-sourcetitle>Brain Res</ref-sourcetitle><ref-publicationyear first="2018"/><ref-volisspag><voliss volume="31"/><pagerange first="30019"/></ref-volisspag></ref-info><ref-fulltext>Chalazonitis A, Rao M. Enteric nervous system manifestations of neurodegenerative disease. Brain Res. 2018;31:30019-2.</ref-fulltext></reference><reference id="67"><ref-info><ref-title><ref-titletext>Oxidative stress: Key player in gastrointestinal complications of diabetes</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">78651426671</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>P.</ce:initials><ce:indexed-name>Kashyap P.</ce:indexed-name><ce:surname>Kashyap</ce:surname></author><author seq="2"><ce:initials>G.</ce:initials><ce:indexed-name>Farrugia G.</ce:indexed-name><ce:surname>Farrugia</ce:surname></author></ref-authors><ref-sourcetitle>Neurogastroenterol Motil</ref-sourcetitle><ref-publicationyear first="2011"/><ref-volisspag><voliss volume="23"/><pagerange first="111" last="114"/></ref-volisspag><ref-text>1:CAS:528:DC%2BC3MXisV2qtrw%3D 21226884 4441525</ref-text></ref-info><ref-fulltext>Kashyap P, Farrugia G. Oxidative stress: key player in gastrointestinal complications of diabetes. Neurogastroenterol Motil. 2011;23:111-4.</ref-fulltext></reference><reference id="68"><ref-info><ref-title><ref-titletext>Oxidative stress and cellular pathologies in Parkinson's disease</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">85035784486</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>L.</ce:initials><ce:indexed-name>Puspita L.</ce:indexed-name><ce:surname>Puspita</ce:surname></author><author seq="2"><ce:initials>S.Y.</ce:initials><ce:indexed-name>Chung S.Y.</ce:indexed-name><ce:surname>Chung</ce:surname></author><author seq="3"><ce:initials>J.W.</ce:initials><ce:indexed-name>Shim J.W.</ce:indexed-name><ce:surname>Shim</ce:surname></author></ref-authors><ref-sourcetitle>Mol Brain</ref-sourcetitle><ref-publicationyear first="2017"/><ref-volisspag><voliss volume="10"/><pagerange first="17" last="0340"/></ref-volisspag></ref-info><ref-fulltext>Puspita L, Chung SY, Shim JW. Oxidative stress and cellular pathologies in Parkinson's disease. Mol Brain. 2017;10:017-0340.</ref-fulltext></reference><reference id="69"><ref-info><ref-title><ref-titletext>A review of some aspects of the pharmacology of levodopa</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">0018245071</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>J.G.</ce:initials><ce:indexed-name>Morris J.G.</ce:indexed-name><ce:surname>Morris</ce:surname></author></ref-authors><ref-sourcetitle>Clin Exp Neurol</ref-sourcetitle><ref-publicationyear first="1978"/><ref-volisspag><voliss volume="15"/><pagerange first="24" last="50"/></ref-volisspag><ref-text>1:STN:280:DyaL3c%2FjsVOmsA%3D%3D 386308</ref-text></ref-info><ref-fulltext>Morris JG. A review of some aspects of the pharmacology of levodopa. Clin Exp Neurol. 1978;15:24-50.</ref-fulltext></reference><reference id="70"><ref-info><ref-title><ref-titletext>Adverse events from the treatment of Parkinson's disease</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">50949128558</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>K.L.</ce:initials><ce:indexed-name>Chou K.L.</ce:indexed-name><ce:surname>Chou</ce:surname></author></ref-authors><ref-sourcetitle>Neurol Clin</ref-sourcetitle><ref-publicationyear first="2008"/><ref-volisspag><voliss volume="26"/><pagerange first="03"/></ref-volisspag></ref-info><ref-fulltext>Chou KL. Adverse events from the treatment of Parkinson's disease. Neurol Clin. 2008;26:003.</ref-fulltext></reference><reference id="71"><ref-info><ref-title><ref-titletext>The management of orthostatic hypotension in Parkinson's disease</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84883533627</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>A.</ce:initials><ce:indexed-name>Sanchez-Ferro A.</ce:indexed-name><ce:surname>Sánchez-Ferro</ce:surname></author><author seq="2"><ce:initials>J.</ce:initials><ce:indexed-name>Benito-Leon J.</ce:indexed-name><ce:surname>Benito-León</ce:surname></author><author seq="3"><ce:initials>J.C.</ce:initials><ce:indexed-name>Gomez-Esteban J.C.</ce:indexed-name><ce:surname>Gómez-Esteban</ce:surname></author></ref-authors><ref-sourcetitle>Front Neurol</ref-sourcetitle><ref-publicationyear first="2013"/><ref-volisspag><voliss volume="4"/><pagerange first="64"/></ref-volisspag><ref-text>10.3389/fneur.2013.00064 23772219 3677136</ref-text></ref-info><ref-fulltext>Sánchez-Ferro Á, Benito-León J, Gómez-Esteban JC. The management of orthostatic hypotension in Parkinson's disease. Front Neurol. 2013;4:64. https://doi.org/10.3389/fneur.2013.00064.</ref-fulltext></reference><reference id="72"><ref-info><ref-title><ref-titletext>Correlation between genetic polymorphisms within IL-1B and TLR4 genes and cancer risk in a Russian population: A case-control study</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84902996977</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>A.G.</ce:initials><ce:indexed-name>Kutikhin A.G.</ce:indexed-name><ce:surname>Kutikhin</ce:surname></author><author seq="2"><ce:initials>A.E.</ce:initials><ce:indexed-name>Yuzhalin A.E.</ce:indexed-name><ce:surname>Yuzhalin</ce:surname></author><author seq="3"><ce:initials>A.N.</ce:initials><ce:indexed-name>Volkov A.N.</ce:indexed-name><ce:surname>Volkov</ce:surname></author><author seq="4"><ce:initials>A.S.</ce:initials><ce:indexed-name>Zhivotovskiy A.S.</ce:indexed-name><ce:surname>Zhivotovskiy</ce:surname></author><author seq="5"><ce:initials>E.B.</ce:initials><ce:indexed-name>Brusina E.B.</ce:indexed-name><ce:surname>Brusina</ce:surname></author></ref-authors><ref-sourcetitle>Tumour Biol</ref-sourcetitle><ref-publicationyear first="2014"/><ref-volisspag><voliss volume="35"/><pagerange first="4821" last="4830"/></ref-volisspag><ref-text>1:CAS:528:DC%2BC2cXntlOrsr0%3D 24446182</ref-text></ref-info><ref-fulltext>Kutikhin AG, Yuzhalin AE, Volkov AN, Zhivotovskiy AS, Brusina EB. Correlation between genetic polymorphisms within IL-1B and TLR4 genes and cancer risk in a Russian population: a case-control study. Tumour Biol. 2014;35:4821-30.</ref-fulltext></reference><reference id="73"><ref-info><ref-title><ref-titletext>Proteomic profiling for cardiovascular biomarker discovery in orthostatic hypotension</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">85044118059</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>M.</ce:initials><ce:indexed-name>Johansson M.</ce:indexed-name><ce:surname>Johansson</ce:surname></author><author seq="2"><ce:initials>F.</ce:initials><ce:indexed-name>Ricci F.</ce:indexed-name><ce:surname>Ricci</ce:surname></author><author seq="3"><ce:initials>N.</ce:initials><ce:indexed-name>Aung N.</ce:indexed-name><ce:surname>Aung</ce:surname></author><author seq="4"><ce:initials>R.</ce:initials><ce:indexed-name>Sutton R.</ce:indexed-name><ce:surname>Sutton</ce:surname></author><author seq="5"><ce:initials>O.</ce:initials><ce:indexed-name>Melander O.</ce:indexed-name><ce:surname>Melander</ce:surname></author><author seq="6"><ce:initials>A.</ce:initials><ce:indexed-name>Fedorowski A.</ce:indexed-name><ce:surname>Fedorowski</ce:surname></author></ref-authors><ref-sourcetitle>Hypertension</ref-sourcetitle><ref-publicationyear first="2018"/><ref-volisspag><voliss volume="71"/><pagerange first="465" last="472"/></ref-volisspag><ref-text>1:CAS:528:DC%2BC1cXit1ymurk%3D 29295851</ref-text></ref-info><ref-fulltext>Johansson M, Ricci F, Aung N, Sutton R, Melander O, Fedorowski A. Proteomic profiling for cardiovascular biomarker discovery in orthostatic hypotension. Hypertension. 2018;71:465-72.</ref-fulltext></reference><reference id="74"><ref-info><ref-title><ref-titletext>Inflammatory biomarker profiling in classical orthostatic hypotension: Insights from the SYSTEMA cohort</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">85044124578</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>M.</ce:initials><ce:indexed-name>Johansson M.</ce:indexed-name><ce:surname>Johansson</ce:surname></author><author seq="2"><ce:initials>F.</ce:initials><ce:indexed-name>Ricci F.</ce:indexed-name><ce:surname>Ricci</ce:surname></author><author seq="3"><ce:initials>N.</ce:initials><ce:indexed-name>Aung N.</ce:indexed-name><ce:surname>Aung</ce:surname></author><author seq="4"><ce:initials>R.</ce:initials><ce:indexed-name>Sutton R.</ce:indexed-name><ce:surname>Sutton</ce:surname></author><author seq="5"><ce:initials>O.</ce:initials><ce:indexed-name>Melander O.</ce:indexed-name><ce:surname>Melander</ce:surname></author><author seq="6"><ce:initials>A.</ce:initials><ce:indexed-name>Fedorowski A.</ce:indexed-name><ce:surname>Fedorowski</ce:surname></author></ref-authors><ref-sourcetitle>Int J Cardiol</ref-sourcetitle><ref-publicationyear first="2018"/><ref-volisspag><voliss volume="259"/><pagerange first="192" last="197"/></ref-volisspag><ref-text>29579600</ref-text></ref-info><ref-fulltext>Johansson M, Ricci F, Aung N, Sutton R, Melander O, Fedorowski A. Inflammatory biomarker profiling in classical orthostatic hypotension: insights from the SYSTEMA cohort. Int J Cardiol. 2018;259:192-7.</ref-fulltext></reference><reference id="75"><ref-info><ref-title><ref-titletext>Clinical variables and ethnicity may influenced by polymorphism of CAT -262C/T and MnSOD 47C/T antioxidant enzymes in Algerian type1 diabetes without complications</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">85047808951</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>A.</ce:initials><ce:indexed-name>Eddaikra A.</ce:indexed-name><ce:surname>Eddaikra</ce:surname></author><author seq="2"><ce:initials>H.</ce:initials><ce:indexed-name>Amroun H.</ce:indexed-name><ce:surname>Amroun</ce:surname></author><author seq="3"><ce:initials>R.</ce:initials><ce:indexed-name>Raache R.</ce:indexed-name><ce:surname>Raache</ce:surname></author><author seq="4"><ce:initials>A.</ce:initials><ce:indexed-name>Galleze A.</ce:indexed-name><ce:surname>Galleze</ce:surname></author><author seq="5"><ce:initials>N.</ce:initials><ce:indexed-name>Abdallah-Elhadj N.</ce:indexed-name><ce:surname>Abdallah-Elhadj</ce:surname></author><author seq="6"><ce:initials>M.</ce:initials><ce:indexed-name>Azzouz M.</ce:indexed-name><ce:surname>Azzouz</ce:surname></author><author seq="7"><ce:initials>F.</ce:initials><ce:indexed-name>Mecabih F.</ce:indexed-name><ce:surname>Mecabih</ce:surname></author><author seq="8"><ce:initials>B.</ce:initials><ce:indexed-name>Mechti B.</ce:indexed-name><ce:surname>Mechti</ce:surname></author><author seq="9"><ce:initials>M.C.</ce:initials><ce:indexed-name>Abbadi M.C.</ce:indexed-name><ce:surname>Abbadi</ce:surname></author><author seq="10"><ce:initials>C.</ce:initials><ce:indexed-name>Touil-Boukoffa C.</ce:indexed-name><ce:surname>Touil-Boukoffa</ce:surname></author><author seq="11"><ce:initials>N.</ce:initials><ce:indexed-name>Attal N.</ce:indexed-name><ce:surname>Attal</ce:surname></author></ref-authors><ref-sourcetitle>Gene</ref-sourcetitle><ref-publicationyear first="2018"/><ref-volisspag><voliss volume="670"/><pagerange first="182" last="192"/></ref-volisspag><ref-text>1:CAS:528:DC%2BC1cXhtVKnurrK 29859283</ref-text></ref-info><ref-fulltext>Eddaikra A, Amroun H, Raache R, Galleze A, Abdallah-Elhadj N, Azzouz M, Mecabih F, Mechti B, Abbadi MC, Touil-Boukoffa C, Attal N. Clinical variables and ethnicity may influenced by polymorphism of CAT -262C/T and MnSOD 47C/T antioxidant enzymes in Algerian type1 diabetes without complications. Gene. 2018;670:182-92.</ref-fulltext></reference><reference id="76"><ref-info><ref-title><ref-titletext>Neuronal nitric oxide synthase polymorphisms in obsessive-compulsive disorder</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84991037014</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>M.</ce:initials><ce:indexed-name>Topaloglu M.</ce:indexed-name><ce:surname>Topaloglu</ce:surname></author><author seq="2"><ce:initials>E.</ce:initials><ce:indexed-name>Tuzun E.</ce:indexed-name><ce:surname>Tuzun</ce:surname></author><author seq="3"><ce:initials>H.</ce:initials><ce:indexed-name>Gulec H.</ce:indexed-name><ce:surname>Gulec</ce:surname></author><author seq="4"><ce:initials>E.S.</ce:initials><ce:indexed-name>Bireller E.S.</ce:indexed-name><ce:surname>Bireller</ce:surname></author><author seq="5"><ce:initials>B.</ce:initials><ce:indexed-name>Cakmakoglu B.</ce:indexed-name><ce:surname>Cakmakoglu</ce:surname></author><author seq="6"><ce:initials>C.I.</ce:initials><ce:indexed-name>Kucukali C.I.</ce:indexed-name><ce:surname>Kucukali</ce:surname></author></ref-authors><ref-sourcetitle>Nord J Psychiatry</ref-sourcetitle><ref-publicationyear first="2017"/><ref-volisspag><voliss volume="71"/><pagerange first="115" last="119"/></ref-volisspag><ref-text>27739347</ref-text></ref-info><ref-fulltext>Topaloglu M, Tuzun E, Gulec H, Bireller ES, Cakmakoglu B, Kucukali CI. Neuronal nitric oxide synthase polymorphisms in obsessive-compulsive disorder. Nord J Psychiatry. 2017;71:115-9.</ref-fulltext></reference><reference id="77"><ref-info><ref-title><ref-titletext>Association of a functional variant of the nitric oxide synthase 1 gene with personality, anxiety, and depressiveness</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84867518991</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>T.</ce:initials><ce:indexed-name>Kurrikoff T.</ce:indexed-name><ce:surname>Kurrikoff</ce:surname></author><author seq="2"><ce:initials>K.P.</ce:initials><ce:indexed-name>Lesch K.P.</ce:indexed-name><ce:surname>Lesch</ce:surname></author><author seq="3"><ce:initials>E.</ce:initials><ce:indexed-name>Kiive E.</ce:indexed-name><ce:surname>Kiive</ce:surname></author><author seq="4"><ce:initials>K.</ce:initials><ce:indexed-name>Konstabel K.</ce:indexed-name><ce:surname>Konstabel</ce:surname></author><author seq="5"><ce:initials>S.</ce:initials><ce:indexed-name>Herterich S.</ce:indexed-name><ce:surname>Herterich</ce:surname></author><author seq="6"><ce:initials>T.</ce:initials><ce:indexed-name>Veidebaum T.</ce:indexed-name><ce:surname>Veidebaum</ce:surname></author><author seq="7"><ce:initials>A.</ce:initials><ce:indexed-name>Reif A.</ce:indexed-name><ce:surname>Reif</ce:surname></author><author seq="8"><ce:initials>J.</ce:initials><ce:indexed-name>Harro J.</ce:indexed-name><ce:surname>Harro</ce:surname></author></ref-authors><ref-sourcetitle>Dev Psychopathol</ref-sourcetitle><ref-publicationyear first="2012"/><ref-volisspag><voliss volume="24"/><pagerange first="1225" last="1235"/></ref-volisspag><ref-text>23062293</ref-text></ref-info><ref-fulltext>Kurrikoff T, Lesch KP, Kiive E, Konstabel K, Herterich S, Veidebaum T, Reif A, Harro J. Association of a functional variant of the nitric oxide synthase 1 gene with personality, anxiety, and depressiveness. Dev Psychopathol. 2012;24:1225-35.</ref-fulltext></reference><reference id="78"><ref-info><ref-title><ref-titletext>L-DOPA-induced dyskinesias, motor fluctuations and health-related quality of life: The COPARK survey</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">85030658671</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>S.</ce:initials><ce:indexed-name>Perez-Lloret S.</ce:indexed-name><ce:surname>Perez-Lloret</ce:surname></author><author seq="2"><ce:initials>L.</ce:initials><ce:indexed-name>Negre-Pages L.</ce:indexed-name><ce:surname>Negre-Pages</ce:surname></author><author seq="3"><ce:initials>P.</ce:initials><ce:indexed-name>Damier P.</ce:indexed-name><ce:surname>Damier</ce:surname></author><author seq="4"><ce:initials>A.</ce:initials><ce:indexed-name>Delval A.</ce:indexed-name><ce:surname>Delval</ce:surname></author><author seq="5"><ce:initials>P.</ce:initials><ce:indexed-name>Derkinderen P.</ce:indexed-name><ce:surname>Derkinderen</ce:surname></author><author seq="6"><ce:initials>A.</ce:initials><ce:indexed-name>Destee A.</ce:indexed-name><ce:surname>Destee</ce:surname></author><author seq="7"><ce:initials>W.G.</ce:initials><ce:indexed-name>Meissner W.G.</ce:indexed-name><ce:surname>Meissner</ce:surname></author><author seq="8"><ce:initials>F.</ce:initials><ce:indexed-name>Tison F.</ce:indexed-name><ce:surname>Tison</ce:surname></author><author seq="9"><ce:initials>O.</ce:initials><ce:indexed-name>Rascol O.</ce:indexed-name><ce:surname>Rascol</ce:surname></author></ref-authors><ref-sourcetitle>Eur J Neurol</ref-sourcetitle><ref-publicationyear first="2017"/><ref-volisspag><voliss volume="24"/><pagerange first="1532" last="1538"/></ref-volisspag><ref-text>1:STN:280:DC%2BC1M%2Fhs1Sgsw%3D%3D 28940893</ref-text></ref-info><ref-fulltext>Perez-Lloret S, Negre-Pages L, Damier P, Delval A, Derkinderen P, Destee A, Meissner WG, Tison F, Rascol O. L-DOPA-induced dyskinesias, motor fluctuations and health-related quality of life: the COPARK survey. Eur J Neurol. 2017;24:1532-8.</ref-fulltext></reference><reference id="79"><ref-info><ref-title><ref-titletext>Targeted therapies for Parkinson's disease: From genetics to the clinic</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">85046011853</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>S.P.</ce:initials><ce:indexed-name>Sardi S.P.</ce:indexed-name><ce:surname>Sardi</ce:surname></author><author seq="2"><ce:initials>J.M.</ce:initials><ce:indexed-name>Cedarbaum J.M.</ce:indexed-name><ce:surname>Cedarbaum</ce:surname></author><author seq="3"><ce:initials>P.</ce:initials><ce:indexed-name>Brundin P.</ce:indexed-name><ce:surname>Brundin</ce:surname></author></ref-authors><ref-sourcetitle>Mov Disord</ref-sourcetitle><ref-publicationyear first="2018"/><ref-volisspag><voliss volume="33"/><pagerange first="684" last="696"/></ref-volisspag><ref-text>29704272 6282975</ref-text></ref-info><ref-fulltext>Sardi SP, Cedarbaum JM, Brundin P. Targeted therapies for Parkinson's disease: from genetics to the clinic. Mov Disord. 2018;33:684-96.</ref-fulltext></reference></bibliography></tail></bibrecord></item></abstracts-retrieval-response>